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Abstract
This dissertation focuses on rationalised DNA design as a tool for the discovery
and development of new therapeutic entities, as well as understanding the biological
function of DNA beyond the storage of genetic information. The study is comprised
of two main areas of study: (i) the use of DNA as a coding unit to illustrate the
relationship between code-diversity and dynamics of self-assembly; and (ii) the use
of DNA as an active unit that interacts and regulates a target protein.
In the study of DNA as a coding unit in code-diversity and dynamics of self-assembly,
we developed the DNA-Based Diversity Modelling and Analysis (DDMA) method.
Using Polymerase Chain Reaction (PCR) and Real Time Polymerase Chain Reac-
tion (RT-PCR), we studied the diversity and evolution of synthetic oligonucleotide
populations. The manipulation of critical conditions, with monitoring and inter-
pretation of their effects, lead to understanding how PCR amplification unfolding
could reshape a population. This new take on an old technology has great value for
the study of: (a) code-diversity, convenient in a DNA-based selection method, so
semi-quantitation can evaluate a selection development and the population’s beha-
viour can indicate the quality; (b) self-assembly dynamics, for the simulation of a
real evolution, emulating a society where selective pressures direct the population’s
adaptation; and (c) development of high-entropy DNA structures, in order to under-
stand how similar unspecific DNA structures are formed in certain pathologies, such
as in auto-immune diseases.
i
To explore DNA as an active unit in Tumour Necrosis Factor α (TNF-α) inter-
action and activity modulation, we investigate DNA’s influence on its spatial con-
formation by physical environment regulation. Active TNF-α is a trimer and the
protein-protein interactions between its monomers are a promising target for drug
development. It has been hypothesised that TNF-α forms a very intricate network
after its activation between its subunits and receptors, but the mechanism is still not
completely clear. During our research, we estimate the non-specific DNA binding to
TNF-α in the low micro-molar range. Cell toxicity assays confirm this interaction,
where DNA consistently enhances TNF-α’s cytotoxic effect. Further binding and
structural studies lead to the same conclusion that DNA binds and interferes with
TNF-α structure. From this protein-DNA interaction study, a new set of tools to
regulate TNF-α’s biological activity can be developed and its own biology can be
unveiled.
ii
To Eli and HeeChang.
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1
Introduction
1.1 Project Origin and Unexpected Observations
Rational drug design was the origin of this project. Multivalent interaction exempli-
fied by, for example, Rao et al. paper was an inspiration for designing and improving
a molecule that could, one day, be used in therapy. In this paper, the development of
a trivalent system using vancomycin and D-Ala-D-Ala (dAdA) generated an affinity
25 times higher than biotin and avidin. Plus, this polyvalent system has the possib-
ility of being further modulated [1]. This was our aim, to improve molecules already
known, integrating them in a complex that would leave space for modulation.
Our initial challenge was to merge two incredible powerful DNA-based technologies:
DNA-Encoded Chemical Libraries (DECL) and Systematic Evolution of Ligands by
Exponential Enrichment (SELEX). The goal was clear, we would start by improving
the affinity of a known ligand with an aptamer selection. An aptamer library with a
large theoretical number of unique sequences, more than one trillion, would hybrid-
ise with oligonucleotides carrying a small molecule. In an effort to further optimise
the aptamer selection, we used oligonucleotides with shorter hybridisation domains,
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recreating the concept of dynamic combination of pharmacophores [2, 3]. This would
enable the best fits to be recognised and newly generated in a large pool of possible
ligands with varying affinities, leading to a more robust affinity maturation.
The choice of DNA as the moiety to modulate the affinity arose from its hydro-
philicity, since active sites are usually quite hydrophobic [4]. The improved balance
between hydrophobicity/hydrophilicity could bring us small molecules hybrids with
improved pharmacokinetic characteristics. Also, the possibility to generate large
DNA aptamers populations, by chemical synthesis, and to have a straightforward
final sequencing step, to decode the pool of interest, were huge advantages.
The targets we chose were proteins involved in immunity, such as cyclophilins, in-
terleukins (IL), and TNF-α. We started with cyclophilins, which are a family of
proteins with several isoforms that can be inhibited by the immunosuppressive drug
cyclosporin and its derivatives. We wanted to develop hybrid molecules able to dis-
tinguish isoforms, so a more desirable therapy with less side effects could be achieved.
From this family, we focused on cyclophilin A and cyclosporin A, which have affinity
in the low nano-molar.
TNF-α and IL were also interesting targets due to the lack of small molecule thera-
peutic options. Nowadays, only antibody (Ab)-based therapies are available. With
the surge of autoimmune diseases in our world, it seems insufficient the arsenal we
have to control and inhibit these targets. We selected TNF-α because it is a protein
related and central to a large range of immune diseases. Given its trimeric conform-
ation TNF-α, we hypothesised that it could be helpful to develop a better molecule
if the three subunits active pockets would be explored or if the protein-protein in-
teractions among monomers were disrupted.
These were the starting points of our project. The initial experiments were quite
promising. The SELEX protocol worked and, unlike most, was a solution-based se-
lection, without protein immobilisation. Also, the preliminary activity assays of the
2
hybrid molecule were interesting and the isoform specificity of the hybrid seemed
possible to achieve.
However, one day while checking the DNA pool after a selection round using RT-
PCR, we met an unexpected result. The amplification curves were bell-shaped, in-
stead of the classical sigmoidal-shape. After thorough investigation, we understood
it was not a mistake/contamination, but an interesting phenomenon that could be
manipulated. This effect had been observed before, but was never explored. The
study of this observation originated the project ”DDMA”.
In parallel, we continued with the main plan for the search and development of an
improved molecule for immunological disease management. This time, the repeated
observation of unexpected protein-DNA interaction awoke our inquiring minds. The
further investigation of these unspecific physical interactions between DNA and TNF-
α translated into evident increased biological activity and structural changes. We
did not let this other serendipitous event pass in vain and the second half of this
PhD project was born, ”Physical Environment Regulation of TNF-α Activity”.
Both projects started as a study of DNA and its physical-chemical properties. They
evolved into the study of DNA’s ability to modulate protein-protein interactions and
DNA’s ability to self-assemble according to pairing rules in a highly heterogeneous
population.
As oligonucleotides are no longer seen as static vessels of genetic information, our
work becomes more relevant under today’s biotechnological developments. DNA is
becoming an exemplary tool in coding non-genetic information and assembling into
nanostructures.
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1.2 Deoxyribonucleic Acid
1.2.1 Chemical and Physical Properties
Deoxyribonucleic acid (DNA) was first described in 1953 by Watson and Crick [5].
DNA is a deoxyoligonucleotide polymer with two antiparallel helical strands organ-
ised around one axis. The monomers are linked by covalent bonds between the 3’-end
sugar and the 5’-end phosphate, the phosphodiester bonds, and form the single-
stranded DNA (ssDNA). Each monomer has a nucleobase, which can be purinic
(adenine (A), guanine (G)) or pyrimidinic (cytosine (C), thymine (T)), a deoxyribose,
and a phosphate group. These have strict pairing rules of purine with pyrimidine,
A-T and C-G, and hydrogen bonds between them in two different chains are estab-
lished, generating double-stranded DNA (dsDNA).
The dsDNA forms major and minor grooves, which are determined by the distance
between the nearest phosphorus atoms across the chain. A macromolecule binding to
DNA usually occurs in the minor groove and shifts its conformation. The DNA mo-
lecule’s torsional rigidity increases with small twisting and decreases with untwisting
[6]. DNA has a diameter around 2 nm, with a structural repeat around 3.5 nm, and
persistence length around 50 nm [7]. It is packed around histones, becoming highly
condensed, and forming nucleosomes.
DNA interacts with other proteins at various levels. For instance, proteins regulate
DNA translation, replication and transcription, which, in turn, generates proteins
that participate in molecular events [8, 9].
DNA is a great biotechnological tool due to its characteristics, ease of use, and pos-
sibility to chemically synthesise in a relatively inexpensive and easy way. To start
with its basic function, DNA is able to support an extremely large amount of in-
formation, e.g., cells can store one to 2 GB of data in 7 pg. Modifying the classical
nucleobases expands this ability even further. For example, in vivo, nucleobases can
4
be modified directly by methylation, which modulates gene expression, as studied
by the emerging field of epigenetics. Another very attractive feature of DNA is the
possibility to be operated at the molecular level by a plethora of enzymes with high
accuracy and efficiency. Examples of such tools are ligases (attachment), polymerases
(elongation), endonucleases (specific site cleavage), or exonucleases (free 3’- or 5’-end
cleavage) [10].
DNA chemical synthesis is based on automated solid-phase phosphoramidite chem-
istry synthesis, and is efficient up to around 200 nucleotides [11, 12]. The DNA se-
quence design is also an uncomplicated procedure and it can be done to fulfil certain
pre-determined requirements. For example, the level and length of randomisation in
an aptamer library or the insertion of a restriction site [13].
1.2.2 Interplay with Immune System
Oligonucleotides with sequences with unmethylated Cytidine phosphate Guanosine
(CpG) motifs can induce potent immunostimulation. These motifs work as a signal to
the organism, so it can act against a potential infective entity or uncontrolled growth.
In eukaryotic cells, these motifs are mostly methylated (suppressed transcription).
CpG motifs can [14]:
• stimulate B cells and Antigen Presenting Cells (APC),
• down-regulate macrophage class II major histocompatibility complex (MHC)
antigen (Ag) presentation,
• activate the Nuclear Factor-κB (NF-κB) pathway,
• induce pro-inflammation via T helper 1 cells (Th1 cells) (Toll-like receptor
(TLR) 9), and T helper 2 cells (Th2 cells),
• activate Natural Killer cells (NK cells),
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• and induce polyclonal B cell activation.
CpG motifs are related to a myriad of diseases, from heart disease to Systemic Lupus
Erythematosus (SLE) and Acquired Immune Deficiency Syndrome (AIDS) [15]. In-
sufficient methylation can lead to tumorous cells growth too [16].
CpG motifs are divided in three classes: A, B and C. A-class motifs stimulate NK
cells cells and Interferon α (IFN-α) production. B-class oligonucleotides stimulate
a strong B and NK cells activation and cytokine production. C-class is a mix of A
and B responses, but the oligonucleotides have a phosphorothioate (PS) backbone,
without poly-G, and with palindromes. All classes stimulate TLR signalling [17].
Natural CpG motifs can be hydrolysed in physiological conditions and have low cell
penetration. PS-modifications make DNA more resistant to hydrolysis.
These CpG motifs activity has been studied deeply and different carrier structures
have been evaluated. The size of the carrier DNA influences the activity, where longer
DNA yields higher activity. Several DNA constructs carrying these motifs have been
engineered, e.g., DNA origami delivery systems [18] and Y-shaped structures [19].
CpG motifs can be also used as vaccine adjuvants [20] because they stimulate TNF-
α, IL-6, and IL-12 production [21].
Circulating cell-free DNA (cfDNA) is a valuable tool for diagnostics and therapy
assessment in autoimmune diseases and cancers. cfDNA originates from DNA frag-
ments formed after necrotic cell death [22]. The mean concentration in a healthy per-
son plasma is approximately p2.27˘ 1.51q ng mL´1. This value is elevated in autoim-
mune diseases, such as sarcoidosis (p3.68˘ 2.07q ng mL´1), asthma (p3.02˘ 2.19q ng mL´1),
or chronic obstructive pulmonary disease (COPD) (p3.97˘ 2.03qng mL´1). In on-
cological pathologies, such as non-small-cell lung cancer (p8.02˘ 7.81q ng mL´1), cf-
DNA is also elevated [23]. Some pathologies have been found to be associated with
and classified using anti-DNA Abs, for example SLE [24].
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1.2.3 Amplification
Polymerase Chain Reaction
PCR was initially developed by Kary Mullis to diagnose sickle cell anemia [25]. This
technology made possible the specific amplification of a DNA sequence, using two
shorter DNA sequences (primers) that flank the region of interest. The procedure
is based on three simple steps: denaturation, annealing, and elongation of the oli-
gonucleotide strands. Amplification follows DNA denaturation and annealing of the
primers. Subsequently, the sequence is elongated by polymerase action, see Figure
1.1. The use of a thermostable polymerase, Taq polymerase, makes the PCR more
reliable, sensitive, specific, and robust [26], because it is possible to achieve higher
annealing temperatures.
In each amplification cycle, the DNA population doubles, 2n, where n is the number
of amplification cycles. To ensure an optimal amplification, primers should have
18 to 30 nucleotides, the same length, a 40 to 60% GC content, and no secondary
structures or self-complementarity. Also, MgCl2 increases specificity and DNA hy-
bridisation [27].
Many different iterations of PCR have been developed [28]. In the next paragraphs,
a few examples are described.
It is possible to generate ssDNA using PCR, such as in AsyPCR and modified nested-
PCR. AsyPCR uses an excess of one primer over the other, leading to two phases
of amplification. First, dsDNA production is exponential followed by linear ampli-
fication of ssDNA, which continues until enzyme depletion. Then, for ssDNA, the
amplification is non-exponential and more ssDNA can be obtained with more PCR
cycles [29, 30, 31]. AsyPCR has an efficiency of around 60% compared to normal
PCR, which is more than 90% efficient [32].
Allele-Specific PCR (AS-PCR) is another elegant tool to manipulate DNA ampli-
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fication. In this method, it is possible to amplify an allele that is different in one
or more nucleotides from a template, by feeding the system a longer primer. This
longer primer has, in the extra positions, nucleotides that are complementary to
specific segments in a template. The primer with 3’-end mismatch is not able to
extend and DNA amplification is cancelled [33, 34]. This method is used for Single
Nucleotide Polymorphism (SNP) genotyping, haplotyping, and diagnostics of, for
example, sickle cell anaemia [35]. AS-PCR can detect point mutations because one
position mismatch will destabilise hybridisation [36].
Other technique to manipulate DNA during amplification is mutagenic PCR, where
a polymerase 1000 times more error-prone than when Taq polymerase is used [37].
More recently, Dan Luo’s group developed a thermostable branched DNA nano-
structure that can be used as a modular primer. This can be used for labelling, and
hydrogel or DNA origami formation [38].
Figure 1.1: Schematic of a PCR cycle. The cycle starts with DNA denaturation,
follows with primer annealing and elongation by polymerase action. Adapted with
a permission under the Creative Commons Attribution-Share Alike 3.0 Unported
license [39].
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Real Time Polymerase Chain Reaction Another PCR type is the widely used RT-
PCR, which mostly serves as a quantitative method. The setup is the same as in
common PCR experiments. But, additionally to PCR, there is a correlation between
fluorescence and DNA concentration. This DNA quantification based on developed
fluorescence can be absolute or relative. Absolute quantification determines copy
number and DNA concentration, requiring a standard curve. Relative quantifica-
tion estimates concentration based on the threshold cycle, 2´∆∆Ct , where Ct is the
threshold cycle and the number two represents perfect efficiency at each cycle. RT-
PCR has a wide dynamic range, where Ct and DNA concentration have a linear
relationship. It is a robust technique, easy to scale-up, and to multiplex [40, 41, 42].
Initial template concentration, primers, polymerase and its deactivation, deoxynuc-
leotides (dNTPs), product reannealing and primer-dimer formation influence amp-
lification efficiency. Thus, throughout amplification, efficiency is not constant or
perfect at each cycle. For instance, efficiency is lower in later cycles as the in-
creased DNA template concentration competes for the polymerase [43]. Gevertz et
al. developed a mathematical model that simulates the PCR cycles and calculates
efficiency as a function of cycle number. So,
rDNAsn “ rDNAs0 ˆ p1` εq
n,
where rxsn represents the concentration of x at cycle n and ε is the correction
factor. Nevertheless, efficiency is assumed to be constant until plateau. Hence, it
is possible to monitor dsDNA population by increase of fluorescence signal at each
cycle and this, at the end of each cycle, is proportional to DNA product concentra-
tion [44]. The exponential amplification step must be well defined, so there is a more
reliable concentration determination [45].
Several strategies to create fluorescence during RT-PCR have been developed. For ex-
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ample, the concept of the dsDNA intercalation by a dye, such as SYBR Green I. Free
SYBR Green I is non-fluorescent and when complexed with dsDNA increases fluores-
cence more than a 1,000-fold, with a sensitivity less than 10 pg mL´1. SYBR Green
I intercalates DNA’s minor groove, in a segment around 3.5 base pairs (11.5A) [46].
It is common to use a passive reference dye, such as carboxy-X-rhodamine (ROX)
to normalise the signal and cancel fluorescence variations [47]. Other strategies for
fluorescence development are fluorescently-labelled oligonucleotides, hydrolysis or hy-
bridisation probes, and molecular beacons.
Furthermore, RT-PCR can provide information about the oligonucleotides melting
curve, which indicates the dsDNA pool nature. The method relies on subjecting the
PCR product to a wide range of temperatures until they denature. Shorter duplexes
and mismatches have a lower melting temperature than the expected size product
[27].
1.2.4 Uses in Biotechnology
The DNA molecule is programmable, flexible, easily synthesised and modified, non-
toxic, and biocompatible. These features make it a desirable solution for many
biotechnological applications and suitable for a vast range of functions. DNA can
adopt different conformations and adapt to different conditions [7]. Increasingly, it
is being used as a theranostic tool, combining diagnostic and therapy [48].
In this section, three DNA-based technologies are discussed: SELEX, DECL, and
organised structures. It must be emphasised that the volume of information cur-
rently available regarding other DNA uses in biotechnology is overwhelming and
very frequently of upmost interest.
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Systematic Evolution of Ligands by Exponential Enrichment (SELEX)
Aptamer technology was developed by two distinct groups at the same time, Tuerk
and Gold at the University of Colorado [49] and Ellington and Szostak at the Uni-
versity of Texas in Austin [50]. These performed an in vitro selection of Ribonucleic
acid (RNA) against a ligand by isolating subpopulations from a randomised oligo-
nucleotide pool. The selected single-stranded oligonucleotides folded into a specific
shape, able to interact with the target. This short oligonucleotide, up to 100 bp, was
named aptamer, from the Latin aptus. Aptamers can be DNA or RNA molecules
and form stable secondary structures, which generate hairpins, G-quartets, bulges
or pseudo-knots. Aptamer interactions with a target are held through flat moieties
stacking, hydrogen bonds and molecular shape complementarity [51]. In general,
DNA and RNA aptamers have similar affinities, but DNA selection is simpler be-
cause it only needs direct PCR amplification. RNA must be transcripted, reverse
transcripted, and then amplified [52, 30].
The concept of aptamer selection is called SELEX. SELEX is a cyclic process where
large pools of randomised single-stranded oligonucleotides are selected throughout
several rounds, until a final pool has the desired affinity. This randomised pool is
incubated with a target and, after washing, the bound sequences are eluted and
amplified by PCR. The ssDNA is regenerated from the dsDNA PCR product. The
cycles are repeated until the goal specificity is achieved [53], see Figure 1.2. The
assessment of pool quality can be done by different methods, mostly through affinity
measures. One common way to assess complexity of a pool is by its melting curve
[54]. Using Sanger or deep sequencing, it is possible to decode the sequences. For
instance, Schuetze et al. showed, by sequencing every selection round, that high
affinity aptamers can be found in the first selection rounds, and suggests only three
cycles are necessary [55]. The same group previously used a systematic approach,
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Diversity Standard of Random Oligonucleotides (DiStRO), to determine randomised
oligonucleotides melting curves. They concluded that different diversities had differ-
ent annealing kinetics, with melting curves able to mirror it. Thus, DiStRO can be
used to compare randomised oligonucleotide populations [56].
Figure 1.2: Representation of a SELEX cycle. A typical SELEX cycle starts
with the incubation of the randomised single-stranded oligonucleotides pool with the
target, followed by washing of non-binders, and elution of binders. The binders are
amplified and evaluated. Then, regeneration of single-strands can be done and the
cycle starts again. From Schuetze et al. [55].
Several twists in the SELEX concept have been developed [57]. For instance,
blended-SELEX is based on a setup with a lead molecule linked covalently to a DNA
strand and hybridised to a second oligonucleotide strand with a randomised region.
This methodology was described for the selection of RNA-based irreversible inhibit-
ors of human neutrophil elastase. With this approach, the oligonucleotide sequences
which provide the lead compound with the best reaction to the target are selected
[58]. The same concept is used with a randomised DNA-valine phosphonate library,
an irreversible neutrophil elastase inhibitor [59]. Cell-SELEX is also possible and
generates aptamers against the target molecule on the live cell. It is mostly used
against surface transmembrane proteins difficult to obtain in native conformations
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[60, 61]. In another approach, the non-homologous random recombination lets the
DNA fragments randomly recombine, without sequence homology, according to their
length. This concept is in contrast with SELEX, which explores the sequence space
by enrichment, not by creation of new entities or rare point mutations [62].
Improved DNA sequencing technologies and bioinformatic tools helped to decrease
drastically the number of selection rounds needed, as in single round enrichment of
ligands [63, 64], over-represented libraries [65], an algorithm in post-SELEX to ma-
ture aptamers [66], or predefined binding parameters (smart aptamers) [67].
A vast number of aptamers have been described. Examples are human thrombin
[68], ATP [69], oxytetracycline [70], thrombin [71], coagulation factors [72], ethano-
lamine [73], protein C [74], bisphenol A [75], chimeric aptamers [76], enterotoxin B
[77], streptavidin (SA) [78, 79], tenascin-C [80], digoxin [81], and proteases [82].
Aptamers are compelling molecules to use in therapy, because of their size and ease
to synthesise and modify; characteristics that overlap the advantages of DNA mo-
lecules. Most developed aptamers that are candidates for therapy inhibit protein-
protein interactions, and are antagonists. They reach active pockets or disrupt the
protein spacial conformation [83]. Aptamers with agonistic properties have also been
developed and can co-stimulate receptors [84, 85]. The same group reported the se-
lection of aptamers with activity higher than Abs, where two conjugated aptamers,
one immunomodulatory and the other a target binder, had lower toxicity [86].
Nevertheless, the use of aptamers in therapy is complicated, because it is difficult to
predict DNA pharmacokinetics. DNA’s small size makes it suitable for renal clear-
ance and endonucleases can digest it. Until now, the only aptamer used in the clinic
is a modified RNA aptamer, pegaptanib (Macugen), which has low Kd for the Vas-
cular Endothelial Growth Factor (VEGF). This aptamer is used to treat age-related
macular degeneration [87].
To improve aptamers’ stability in biological fluids, one can use modified nucleotides,
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such as locked nucleic acids or spiegelmers [88], covalently bind the 3’-end to proteins,
or use a PS backbone. Other strategies to improve pharmacokinetics are based on
the conjugation of the aptamer to polyethylene glycol (PEG), for better tissue dis-
tribution [89], or blocking its 3- or 5-end to avoid digestion [90, 91]. In parallel, the
development of new polymerases enables the use of non-natural building blocks and
the continuous improvement of modified oligonucleotide synthesis is improving the
technology. Also, higher affinity aptamers can be created by expanding the genetic
alphabet, such as using nucleobases with higher hydrophobicity. Modifications of
this nature enhance interaction probability and durability between the hydrophilic
oligonucleotide and the hydrophobic active site [4].
All this potential of aptamers can be integrated in many other nanomaterials, such as
gold nanoparticles and nanorods, quantum dots, carbon nanotubes [92], diagnostic
and biosensor chips [93, 94], nanorulers, arrays, DNA origami [95], molecular imaging
[96], hydrogels, films, microcapsules [97], and DNA micelles [98].
DNA-Encoded Chemical Libraries (DECL)
Low molecular weight molecules are ideal starting points for drug discovery and is
compatible with highthroughput screening (HTS) [99]. Although HTS pans millions
of molecules, it has often failed in identifying bona fide hits. In parallel, fragment-
based lead discovery screens lower molecular weight libraries, less than 300 Da. These
fragments are not strong inhibitors, must be used at higher concentrations, and de-
tected with very sensitive tools. Theoretically, due to smaller size, a fragment-based
approach can explore chemical spaces better than HTS.
A simple molecule is a more suitable starting point, because of less potentially un-
wanted effects (e.g., promiscuous interactions) [100] and the possibility of adding
functions. Unlike HTS hits, fragments have high ’ligand efficiency’, which makes
them good candidates for optimisation.
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To further expand the potency of this technology, combinatorial assembly has been
used to increase exponentially the number of compounds in a screening campaign
[101]. Dynamic Combinatorial Chemistry (DCC) proceeds under thermodynamic
control, when all participants are in equilibrium, relying on structures self-assembly.
The interconversion of library members is reversible and the final library constitution
is ruled by thermodynamic stability [102, 2]. DCC virtually covers all possibilities
inside a library and the target becomes the engine of this adaptive process [103].
To overcome the limitations inherent to HTS, DCC and fragment-based lead dis-
covery, DECL strategies have been developed in recent decades [104]. DECL is a
derivation of a well-known and established technology used in Ab development, phage
display. Phage display was first described by George P. Smith, when he reported the
expression of vectors displaying cloned Ags on a phage surface [105]. This techno-
logy relies on the selection cycles of phages that bind an Ag, thus creating soluble
Ab fragments from infected bacteria. The selection process emulates the adaptive
immunity [106]. There is a physical link between genotype and phenotype, so the
DNA encoding the selected Ab can be retrieved. It can develop Abs against virtually
every Ag, which is not possible in vivo [107].
The first concept paper about DECL was written by Brenner and Lerner and it de-
scribes the gradual ’synthesis of a polymer and an oligonucleotide (as a code) on a
linker in split-and-pool cycles’. It characterises chemical entities with genetic tags
attached, which, after binding to a target and eluted, are amplified by PCR [108].
About one decade later, a series of three papers by Halpin and Harbury set the play-
ing field for this emergent trend, and merged DNA technology with drug discovery,
creating real DECL. The papers describe the improvement of DNA-programmed
chemical synthesis [109], selection process [110], and how to improve unprotected
DNA synthesis in solid-phase [111]. This fairly recent technology has advantages
over HTS because it does not need a protein-specific assay, can be miniaturised, and
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is comparatively low cost [112, 113].
More DECL strategies were developed around the same time [114, 115, 116]. A first
basic approach of DECL is the single pharmacophore library, which can be built by
split-and-pool or using complementary oligonucleotides derivatives that can carry
chemical reactions (DNA-templated synthesis), with assisting complementary oligo-
nucleotides [113]. This concept evolved and the Encoded Self-Assembling Chemical
(ESAC) libraries were developed. In ESAC, there is the display of covalently linked
chemical fragments at the end of self-assembled oligonucleotide strands, which carry
a unique DNA sequence for each fragment. After panning, the eluted molecule car-
ries the tag to decode [117, 118], see Figure 1.3. ESAC explores the chelate effect
and the dual molecule display leads to the discovery of two binders, similarly to
fragment-based approaches - dual-pharmacophore strategy [119]. This scaffold iden-
tifies synergistic binding pairs, with high affinity to the target [120].
Figure 1.3: Comparison between phage display and DECL. A phage is the physical
link between the Ab fragment (phenotype) and the gene encoding (genotype) (a).
A small molecule (phenotype) is attached to a DNA strand (genotype) that carries
an unique identifying code (b). Schematic of an affinity selection cycle, where the
binding molecules are eluted and carry the DNA code until final identification, or
resynthesis of a secondary library (c). From Melkko et al. [121].
In an advancement to this original method, the alternated stepwise assembly
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of fragments carrying DNA tags was studied by high-throughput sequencing ’454
technology’ [122, 123]. So far, ESAC technology has been used to improve the affinity
of known ligands, affinity maturation, with a second fragment [124]. Only recently,
the dual-pharmacophore setting identified a de novo pair of fragments because a
major hurdle in this dual-selection was how to retrieve the DNA codes. This was
overcome using an inter-strand code-transfer [125]. Another progress, based on DCC,
lead to the dynamic DECL strategy, where large libraries are assembled, by the
dynamic reshuffling of complementary DNA strands. This reshuffle and the adaptive
pressure by the target can spawn population evolution towards stronger binders [3].
Examples of published DECL campaigns are increasingly more common and a wide
range of targets have been explored, such as SA [126], trypsin [121], albumin [127],
carbonic anhydrase IX [113], IL-2 [128], hydrolases [129], phosphatases [130, 131],
and kinase isoforms [132, 133].
Organised Structures
Nadrian Seeman’s group revolutionised nano-materials with a DNA nanotechnology
named DNA origami. Exploring the well-described DNA properties, the group de-
veloped a new concept to programme and manipulate structures at a nano-level,
exploring DNA’s predictable and controllable self-assembly [134]. These structures
were stable, biocompatible, and able to carry specific sequences used for specific tar-
geting (DNA nano-carriers). Seeman’s group built the first closed polyhedral object
with DNA [135], developed 2D DNA crystals [136, 137], a rotary nano-mechanical
device [138], a 3D crystalline lattice [139], and DNA nanotubes with CpG motifs
[140].
Currently, the widely used DNA origami technology is based on a self-assembly
concept to generate low-entropy DNA structures in a simple and inexpensive way.
The assembly relies on staple strands (shorter complementary ssDNA) that anneal to
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specific sites, folding a scaffold strand (long ssDNA). The recently developed rolling
circle amplification method is also a method for DNA origami production and gen-
erates shorter sequences and DNA nano-ribbons [95].
DNA origami nano-structures can be functionalised [141]. For example, a DNA
nanorobot, able to carry and deliver drugs by using an ’aptamer-encoded logic gate’,
has been developed [142]. However, it has not been seen yet a consistent use of these
outside of the laboratory. There are promising attempts in biosensing, enzymatic
manipulation, drug delivery, and biomimetics. Meanwhile, tools like caDNAno have
been developed to help DNA origami design using a graphical interface [143].
Since the advent of this technology, an incredible number of DNA-based structures
has been made. A few examples are the aptamer-tethered nano-trains, diverse DNA
geometries for increased cell uptake, and the development of artificial biosensors [144].
In parallel, DNA hydrogels have also been described [145], such as dendrimer-like-
DNA structures [146, 147]. DNA hydrogels are 3D, biocompatible, biodegradable,
low cost, easily manipulated, and formed under physiological conditions. Like DNA
origami, DNA hydrogels can be used in drug delivery, tissue engineering, 3D cell
culture [148], or DNA-based nano-devices [149, 150, 20].
1.2.5 Modelling, Computation and Storage
The need of better computation and modelling tools has been an evolving worry in
parallel with technological development. The use of DNA for such ends is a relatively
new solution and is being updated every day. In this section, there is an attempt to
depict the computational world panorama and how we are on the verge of a paradigm
shift, where DNA might be playing a leading role.
An innovative model for DNA computation, ’sticker model’, was developed by Adle-
man, where DNA strands are the physical representation of information and anneal-
ing is the central mechanism. This model has a random access memory without
18
strand extension need, uses no enzymes and is reusable. This ’microprocessor-
controlled parallel robotic workstation’ generates algorithms to be implemented using
DNA-based computers. The model assumes that covalent bonds are not needed in
the computation process, so the system consumes less energy, making the bridge into
a molecular computer [151].
This breakthrough computation method used DNA to solve the Hamiltonian path
problem, which consists of establishing a path between two cities, with an incom-
plete group of roads. DNA strands represent cities and roads, and the sequences are
designed so a road connects to a city. When all strands are mixed, they are able to
self-assemble and solve the problem by themselves [152].
Winfree also suggested that short branched DNA could self-assemble following an
algorithm, making DNA molecules the simplest algorithm modules. To improve this
toolbox, more complex algorithms could be assembled using sticky ends [7]. Also
digital logic circuits were established [153] and a DNA model of a small neural net-
work, using reversible strand displacement [154].
Recent exciting news reported that Microsoft bought ten million strands of syn-
thetic DNA for data storage to Twist Biosciences, a company specialised in etching
techniques similar to chip manufacturing for DNA synthesis. This data storage tech-
nology relies on the durability and density (almost a trillion gigabytes per gram) of
DNA. This robustness is an advantage over current storage because it is resistant to
high temperatures and magnetic fields [155]. Up to now, it is possible to code and
decode a whole set of digital data from DNA [156].
This technological leap could shatter the rules of giant data storage. Today, immense
data centres are being built because of the endless accumulation of data we all gen-
erate every day. Plus, the revolutionary concept of Internet of Things will change
the way we humans interact with devices and will increase dramatically the amount
of data to store in the world. It is predicted that by 2020, 50 billion devices will
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be connected to the Internet and generate 44 ZB of data every year [157]. Current
storage is not enough to accommodate these numbers.
Today’s status of DNA storage can be seen on Figure 1.4. This technology still
has several limitations holding it back: encoding and decoding (replication errors or
reading speed), DNA synthesis (yield and cost), and sequencing. These limitations
are being dealt with and, for example, a strategy for better DNA encoding has been
already developed [158].
For better modelling and computation in a general sense, Tim Palmer suggests a very
strong case for building imprecise computers, given that precise supercomputers are
accurate, but energy expensive. The claim is that it is not always necessary to
have deterministic Turing machines and that some randomness improves the sys-
tem. ’Energy-efficient hybrid supercomputers’ with different accuracy grades could
be used for different ends, where different levels of precision would be required. For
instance, the human brain is able to power through fantastic levels of computation
in low energy levels, less than 20 W, and give space to something as complex as
creativity, jumping between low- and high-energy determinism [159, 160].
Figure 1.4: Comparison between data storage power and limits of a hard disk, a
flash memory, and bacterial DNA. Adapted from Extance [161].
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Population Studies Limitations To complete this section, it is needed to discuss the
roadblocks existent in modelling populations. Similarly challenging as to building a
supercomputer with low energy consumption is to analyse and model a large society,
in which each individual is characteristically different. It is often very difficult to
collect and analyse reliable data from hundreds to thousands of individuals, not to
mention a large and highly diverse society, e.g., human society.
In a more and more inter-connected world, it is less likely that we can treat any
group of people as an isolated population. The concepts used nowadays plus the
statistical tools are insufficient and frequently lag in regards of accuracy, precision,
and/or adequacy. As a concrete example, there is an urgent need for improving
the statistical models for species distribution, in order to keep up to follow drastic
changes caused by climate change.
Austin reviews several methods and concludes that the tools used are limited and
theory is missing. Most of all, data extension still determines the fit, which is a
huge limitation. The improvement of population studies tools with more complex
models could improve the selection of predictor variables [162]. Citing Caswell [37],
theoretical problems in ecology can be summed as:
• exploring the consequences of a theory, determining the possibility of a theor-
etical model contributing to an ecological one,
• demonstrating the link between seemingly unrelated theories,
• robustness evaluation,
• developing mathematical methods for theoretical models analysis,
• finding the simplest model able to mimic the observation,
• and designing empirical and/or experimental tests of the theory.
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In the concrete case of population adaptation, it is possible to summarise in two
parameters: colonisation of new environments by newly adapted populations and
local adaptation in a heterogeneous environment. These can include exposure to a
novel host or food resource, a new biophysical environment, a new predator, or a
competitor [163].
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1.3 Tumour Necrosis Factor α
TNF-α is a pleiotropic pro-inflammatory cytokine mainly produced by activated
macrophages and T cells. It was first described as an endotoxin that caused hem-
orrhagic necrosis of sarcomas. TNF-α’s many biological roles have been thoroughly
reviewed [164], but they can be summarised as being mostly related to inflammation
and immune responses. TNF-α causes cell death through necroptosis, which is a
controlled necrosis that follows signal transduction pathways [165, 166].
This cytokine has an important role in the pathological development of most autoim-
mune and inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel
disease, uveitis, SLE, or psoriasis. In the nervous system, TNF-α’s inflammation in-
duction can be linked to Alzheimer’s disease, multiple sclerosis, depression, and other
neurological disorders. Cardiovascular, respiratory, and metabolic diseases can also
be primed by TNF-α’s inflammation pathway. Plus, TNF-α is heavily involved in
host defence [167].
TNF-α activates NF-κB, which up-regulates oncogenesis. Knock-outs show nor-
mal development, but are more susceptible to infections and are resistant to lipo-
polysaccharide (LPS) [168]. TNF-α is usually not detected in healthy individuals,
but it is elevated in inflammation and infection, reaching values from 6.3 ˘ 3.6 to
p27.50˘ 10.62q pg mL´1 [169, 170, 171].
1.3.1 Structure and Function
Pro-TNF-α is a transmembrane protein (around 26 kDa) that is cleaved into a sol-
uble form (around 18 kDa) by the TNF-α converting enzyme (TACE). TACE is also
involved in processing other membrane proteins, such as TNF-α receptors, which are
released from the cell membrane and generate soluble receptors that neutralise TNF-
α. TACE is pro- and anti-inflammatory [172]. It is hypothesised that TNF-α is sta-
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bilised by its soluble receptors, keeping its activity and augmenting it [173]. TNF-α
activity is mediated too through high-affinity receptors TNF-α receptor 1 (TNFR1),
expressed ubiquitously, and TNF-α receptor 2 (TNFR2), expressed by haematopoi-
etic cells. Both are homodimers. TNF-α binds almost irreversibly to TNFR1, which
carries a cell death domain: TNFR1 activates mostly pro-inflammatory events and
apoptosis. TNFR2, without cell death domain, binds to TNF-α reversibly and is
linked to tissue repair and angiogenesis.
Thus far, TNF-α activation has been attached to the macrophage, which is activated
at the inflammation site [174]. Interestingly, this process is associated with release of
DNA. It has been reported that high concentrations of PS oligonucleotides increase
TNF-α synthesis in vitro. This is probably due to the binding of the polyanionic
structure to cationic charges present on the cell surface, which also increases LPS-
induced TNF-α synthesis [175, 176]. LPS and TNF-α have a synergic effect in cell
death [177], which is inhibited by thalidomide and chromene derivatives [178, 179].
TNF-α and its receptors must oligomerise to initiate a biological response [180].
However, the way the interaction occurs is still not fully understood, but there are
some hypothesis [181]:
• receptor aggregation: three receptors bind to one TNF-α trimer, generating a
signal (Figure 1.5a),
• hexagonal array conformation: an increasing hive of TNF-α trimers bind to
receptor dimers, with each ligand binding to three receptors (Figure 1.5b),
• and molecular switch formation: the ligand binds subunit B and A is released,
so the receptor can bind to a second free site on the ligand, leading to con-
formational changes, and signal transduction (Figure 1.5c).
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(a) (b) (c)
Figure 1.5: Trimerisation hypothesis: three receptors assemble due to the interac-
tion with one TNF-α trimer, generating a signal (a). Expanding-network hypothesis:
an expanding hive-like structure of TNF-α trimers bound to receptor dimers, capping
the receptor can trigger a response (b). Molecular-switch hypothesis: each dimer can
be activated when a ligand binds to B. Then, A disengages from B, so the receptor
can bind through a second site to the ligand. These cause conformation changes that
will alter the cytoplasmic domain of the receptor and lead to signalling (c). Adapted
from Bazzoni at al. [181].
Structure-wise, TNF-α is a non-covalently linked trimer. Each monomer is an
antiparallel β-sandwich and loops in a jellyroll shape [182], with an N -terminal inser-
tion with three more β-strands. Monomers are around 60A long and 30A wide [164].
For biological activity, TNF-α must be a trimer [183] and dissociates at physiological
concentrations (below nano-molar) [184]. TNF-α’s trimer is highly dynamic, as the
monomers assemble and disassemble [185], influenced by concentration, detergents,
and pH [186]. Some drugs, such as suramin, inhibit TNF-α directly by acting on
its structure and disassembling the trimer [187]. Using suramin, it was possible to
model the sequence of TNF deoligomerisation (trimer to dimer to monomer) and it
was estimated that each step had a similar dissociation constant of 0.2 nmol dm´3
[188, 189]. TNF-α also has a heparin-binding domain at the N -terminal of the trimer
[190].
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TNF-α membrane permeability can be enhanced through partial denaturation, which
generates an aggregate with large amounts of α-helix at low pH, high temperatures,
or in the presence of guanidine hydrochloride [191]. The α-helix is not present in the
native conformation and it is hypothesised that it can interact with lipid bilayers,
leading to membrane insertion [192]. In this condition, ion channels are formed,
increasing Na+ influx [193, 194]. These changes are ultimately linked to higher cyto-
toxicity.
1.3.2 Anti-TNF-α Therapy
The well-functioning of the immune system is based on a fragile equilibrium between
pro- and anti-inflammatory players [195]. Unfortunately, TNF-α is very frequently
engaged in the tilting of this balance and its regulation is of upmost importance.
Nonetheless, the discovery and development of small molecular pharmaceutical en-
tities able to tackle this problem has been short and TNF-α remains an elusive
drug discovery target, see Figure 1.6. In this section, it will be briefly revised the
advancements done in this effort.
Nowadays, TNF-α inhibitors licensed and used are mostly anti-TNF-α mono-
clonal Ab-based [196, 197, 198], such as:
• infliximab: a human-murine chimeric immunoglobulin G (IgG) 1,
• adalimumab: a human anti-human TNF-α, generated by phage display,
• golimumab: a fully humanised Ab,
• certolizumab pegol: a PEGylated fragment-antigen binding (Fab),
• or etanercept: a soluble receptor fusion protein, where TNFR2 is coupled to
the IgG’s fragment constant region (Fc).
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Figure 1.6: TNF-α signalling pathways and potential inhibition targets. TNF-α
is involved in a complex net of molecular events and, thus, has a myriad of prob-
able targets to be controlled through. Extracellularly, the inhibition of TNF-α (a)
or its receptor (b) has already yield a few Ab-based therapy options. Plus, TACE
(c) inhibition could prevent the generation of soluble TNF-α. Intracellularly, PDE4
(d), p38 (e) and NF-κB (f) inhibitors are also interesting. NF-κB inhibition would
decrease pro-inflammatory cytokines production and promote cell death in specific
populations, such as cancer cells. Legend : cAMP, cyclic AMP; DD, death domain;
IκB, inhibitor of NF-κB; IKK, IκB kinase; MEKK1, mitogen-activated protein kinase
kinase kinase 1; NIK, NF-κB-inducing kinase; PDE4, phosphodiesterase 4; PKA, pro-
tein kinase A; RIP, receptor-interacting protein; TRADD, TNFR1-associated death
domain-containing protein; TRAF2, TNFR-associated factor 2. Adapted from Pal-
ladino et al. [195].
These inhibitors are used to treat inflammatory diseases, for instance, rheumatoid
arthritis and Crohn’s disease. However, they have typical Ab-based therapy limit-
ations, such as high cost, plenty of side effects, and intravenous administration. In
an effort to improve their pharmacokinetics, PEGylation has been used, increasing
their half-lives.
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The need to develop small molecules for direct TNF-α inhibition arises from the
existing therapies limitations. The ideal small molecule therapy should be orally
administered, have more desirable pharmacodynamic and pharmacokinetic profiles,
have less side effects, be suitable for combination, and have lower cost.
Still, as referred in the previous section, it is largely unknown the exact way TNF-α
interacts with its receptors, which could be the key for efficient inhibition. Protein-
protein interaction or oligomerisation disruption are promising strategies for finding
a more suitable target related to TNF-α’s mode of action. TNF-α dynamic trimer
might be the key for a small molecule target to interfere and prevent correct con-
formation for receptor interaction [199].
Screenings for these molecules have been made. It has been already reported a micro-
molar range inhibitor by disruption of TNF-α, where trimer dissociation increases 600
times [200]. Other small molecules developed are, for example, benzobicyclooctanes
[201], bicyclic pyrazolones [202], or a new class of inhibitors selected by DECL [112].
Artificial binding protein scaffolds with low molecular weight [203], peptides with low
micro-molar affinity [204], bicyclic peptides [205], and other protein-based attempts
[206] have also been developed. Only one anti-TNF-α DNA aptamer, VR11, (Kd of
7 nmol dm´3) has been reported so far [207].
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1.4 Overview
This introduction is an attempt to describe DNA in all valencies. Likewise, we try
to establish parallels between biological and artificial systems, see Table 1.1.
Table 1.1: DNA functions and characteristics.
Biological System Artificial System
Genetic information Central dogma Phage-display, ribosome display
Double helix formation Central dogma DNA origami, DNA hydrogel
Ligand CpG motifs Aptamer (SELEX)
Quaternary number ? DNA computation/Data storage
Negatively charged polymer ? Surface coating
• DNA’s natural function is to be the basic unit of genetic materials for inform-
ation storage inside cells (Subsection 1.2.1). Today, as we try to copy it, there
are artificial setups, such as phage, ribosome display, and DECL (Subsection
1.2.4, DECL). These systems are able to, synthetically, create a link between
genotype and phenotype.
• DNA’s structure itself is also profoundly interesting. Its ability to organise
extremely large amounts of data based on its four bases, which assemble into
a ssDNA and then into a double helix, always following a strict pairing rule,
is essential for information replication. This characteristic also makes DNA
an incredible tool in the development of new biological materials, e.g., DNA
hydrogels or origami. Also, its biocompatibility and overall robustness makes
it an excellent tool for nanobiotechnological applications (Subsection 1.2.4,
Organised Structures).
• More recently, DNA has been explored in biological systems as a ligand. Since
nucleobases are entities that create interactions and establish links with their
milieu, DNA is able to act directly as a ligand. For instance, the presence
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of DNA carrying CpG motifs can induce immune response (Subsection 1.2.2).
Exploring the possible conformations DNA can present, such as loops or G-
quadruplexes, the aptamer technology arose (Subsection 1.2.4, SELEX). Using
aptamer technology, one has the possibility to create a synthetic oligonucleotide
ligand with very high affinity to various targets of interest.
• The physical chemistry of DNA as a highly negatively charged conductive poly-
mer is something being explored too. However, in a biological system, we are
still not very clear regarding its function as a consistent negative charged poly-
mer chain. Nevertheless, this feature is already being used to develop coated
surfaces. One can hypothesise various unspecific interactions that DNA is in-
volved in an organism.
• As mentioned above, the capability of DNA to store large amounts of data
using a quaternary system is quite amazing. In a living system, these four
bases encode a limited number of amino acids. Nowadays, there is an emerging
school of thought lobbying for a paradigm shift of how to store or even compute
data (Subsection 1.2.5). As we know, today it is used a binary system to encode
every digital information. As the world’s data increases exponentially, 0 and
1 might be insufficient. Therefore, the adoption of a quaternary system might
be a solution, with A, G, C, and T.
In this dissertation, I try to understand a bit further the pieces that are still missing
in this puzzle. As a mix of DNA can be considered as a group of random number, we
aim to develop a method to analyse the diversity. Also, we want to explore DNA’s
elusive functions in the biological context.
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Materials and Methods
2.1 General
2.1.1 Materials
All oligonucleotides were purchased from IBA (Germany) or Eurofins (Germany)
and their sequences can be consulted on Tables 2.1, 2.2, 2.3, 2.4, and 2.5. All oligo-
nucleotide and protein concentrations were measured using a NanoDrop instrument
(Thermo Fisher Scientific, Germany), quantifying the absorbance at 260 and 280 nm,
respectively. The L929 cell line from mouse (C3H/An connective tissue) was kindly
provided by the Garbe group (Center for Regenerative Therapies Dresden - CRTD).
The mouse recombinant TNF-α was kindly provided by Dr. Weilin Lin. All data
were plotted using OriginPro 8.6G (OriginLab, USA).
• Agilent (USA): Mx3000P RT-PCR system,
• AppliChem (Germany): Phosphate Buffered Saline (PBS), glycerol, glycine,
ethylenediaminetetraacetic acid (EDTA), low molecular weight Salmon Sperm
DNA (S-DNA), and tris(hydroxymethyl)aminomethane (Tris),
• Applied Photophysics (UK): Chirascan plus,
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Table 2.1: DNA sequences of the templates used on the DDMA project.
Aptamer Libraries
X20 GACAATTCACACACGTCCGCNNNNNNNNNNNNNNNNNNNNATGAGATCGGAAGAGCGTCG
X18 GACAATTCACACACGTCCGCANNNNNNNNNNNNNNNNNNGATGAGATCGGAAGAGCGTCG
X16 GACAATTCACACACGTCCGCATNNNNNNNNNNNNNNNNCGATGAGATCGGAAGAGCGTCG
X14 GACAATTCACACACGTCCGCATTNNNNNNNNNNNNNNCCGATGAGATCGGAAGAGCGTCG
X12 GACAATTCACACACGTCCGCATTCNNNNNNNNNNNNTCCGATGAGATCGGAAGAGCGTCG
X10 GACAATTCACACACGTCCGCATTCGNNNNNNNNNNTTCCGATGAGATCGGAAGAGCGTCG
X8 GACAATTCACACACGTCCGCATTCGTNNNNNNNNGTTCCGATGAGATCGGAAGAGCGTCG
X6 GACAATTCACACACGTCCGCATTCGTANNNNNNAGTTCCGATGAGATCGGAAGAGCGTCG
X4 GACAATTCACACACGTCCGCATTCGTAGNNNNCAGTTCCGATGAGATCGGAAGAGCGTCG
X2 GACAATTCACACACGTCCGCATTCGTAGGNNTCAGTTCCGATGAGATCGGAAGAGCGTCG
High Diversity Libraries
S1 GACAATTCACACACGTCCGCAGTCTGACTGATCACTGGACATGAGATCGGAAGAGCGTCG
S 11 CGACGCTCTTCCGATCTCATGTCCAGTGATCAGTCAGACTGCGGACGTGTGTGAATTGTC
S2 GACAATTCACACACGTCCGCATCTATGCCTGTATTAAAGCATGAGATCGGAAGAGCGTCG
S3 GACAATTCACACACGTCCGCACAAGGGGTCAAGCTCCTGTATGAGATCGGAAGAGCGTCG
S4 GACAATTCACACACGTCCGCCCCTCCCTAAACTTTGCCTAATGAGATCGGAAGAGCGTCG
S5 GACAATTCACACACGTCCGCGGGATCAGCCTGGGGATACAATGAGATCGGAAGAGCGTCG
S6 GACAATTCACACACGTCCGCTATAAATACTACAAGCTCATATGAGATCGGAAGAGCGTCG
S7 GACAATTCACACACGTCCGCGGGGCACCGCCAACAGAGATATGAGATCGGAAGAGCGTCG
S8 GACAATTCACACACGTCCGCCCGGATTATATCCCATGAGGATGAGATCGGAAGAGCGTCG
S9 GACAATTCACACACGTCCGCCTAGTGAAGTGATTCGTTCGATGAGATCGGAAGAGCGTCG
S10 GACAATTCACACACGTCCGCGAACGTTAAGGGTGACCGTCATGAGATCGGAAGAGCGTCG
S1 Mismatched Complementary Templates
S1’M2 CGACGCTCTTCCGATCTCATGTCCAGTGAGTAGTCAGACTGCGGACGTGTGTGAATTGTC
S1’M4 CGACGCTCTTCCGATCTCATGTCCAGTGCGTGGTCAGACTGCGGACGTGTGTGAATTGTC
S1’M6 CGACGCTCTTCCGATCTCATGTCCAGTACGTGTTCAGACTGCGGACGTGTGTGAATTGTC
S1’M8 CGACGCTCTTCCGATCTCATGTCCAGCACGTGTGCAGACTGCGGACGTGTGTGAATTGTC
S1’M10 CGACGCTCTTCCGATCTCATGTCCAACACGTGTGTAGACTGCGGACGTGTGTGAATTGTC
S1’M12 CGACGCTCTTCCGATCTCATGTCCGACACGTGTGTCGACTGCGGACGTGTGTGAATTGTC
S1’M14 CGACGCTCTTCCGATCTCATGTCTGACACGTGTGTCAACTGCGGACGTGTGTGAATTGTC
S1’M16 CGACGCTCTTCCGATCTCATGTATGACACGTGTGTCACCTGCGGACGTGTGTGAATTGTC
S1’M18 CGACGCTCTTCCGATCTCATGCATGACACGTGTGTCACATGCGGACGTGTGTGAATTGTC
S1’M20 CGACGCTCTTCCGATCTCATTCATGACACGTGTGTCACAGGCGGACGTGTGTGAATTGTC
• BD Falcon (USA): 50 mL screw cap reaction tubes,
• BioTek (USA): Synergy H1 Multi-Mode Reader,
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Table 2.2: DNA sequences of the templates used on the DDMA project (continu-
ation).
Randomized Regions Libraries
X2{10 GACAATTCACACACGTCCGCNGNCNGNCNGNTNANTNGNCATGAGATCGGAAGAGCGTCG
X4{5 GACAATTCACACACGTCCGCAGNNTGNNTGNNCANNGGNNATGAGATCGGAAGAGCGTCG
X10{2 GACAATTCACACACGTCCGCNNNNNGACTGNNNNNTGGACATGAGATCGGAAGAGCGTCG
Restriction Enzymes Libraries
XEcoRV GACAATTCACACACGTCCGCNNNNNNNGATATCNNNNNNNATGAGATCGGAAGAGCGTCG
XSmaI GACAATTCACACACGTCCGCNNNNNNNCCCGGGNNNNNNNATGAGATCGGAAGAGCGTCG
Primers
A GACAATTCACACACGTCCGC
A18 GACAATTCACACACGTCC
A15 GACAATTCACACACG
A12 GACAATTCACAC
A20`1 GACAATTCACACACGTCCGCA
A20`5 GACAATTCACACACGTCCGCATTCG
A20`10 GACAATTCACACACGTCCGCATTCGTAGGT
B1 CGACGCTCTTCCGATCTCAT
Other Aptamer Library
Y20 TAGGGAAGAGAAGGACATATGATNNNNNNNNNNNNNNNNNNNNTTGACTAGTACATGACCACTTGA
C TAGGGAAGAGAAGGACATATGAT
D1 TCAAGTGGTCATGTACTAGTCAA
• Carl Roth (Germany): sodium acetate,
• Eppendorf (Germany): cell culture incubator Galaxy 170S (95% humidity, 5%
CO2), table top centrifuge (5424R), DNA, and protein 0.5, 1, and 2 mL low
binding tubes,
• ForteBio (USA): Octet Red 384, 384-well plates with tilted bottom, anti-penta-
His, aminopropylsilane (APS), and amine reactive second generation (ARG)
sensors,
• GE Healthcare (UK): Streptavidin Sepharose High Performance, PD10 desalt-
ing column, and illustra Microspin G-25 columns,
• Greiner Bio-One (Austria): T25, T75, and T175 cell culture flasks with stand-
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Table 2.3: DNA sequences used in the TNF-α binding and activity experiments.
ssDNA
AGGCTGATTCGGTTCATGCGGATCCA
Half-dsDNA
TGGATCCGCATGACATTCGCCGTAAG
CTTACGGCGAATGACCGAATCAGCCT
Full-dsDNA
GACAATTCACACACGTCCGCAGTCTGACTGATCACTGGACATGAGATCGGAAGAGCGTCG
CGACGCTCTTCCGATCTCATGTCCAGTGATCAGTCAGACTGCGGACGTGTGTGAATTGTC
yDNA
TGGATCCGCATGACATTCGCCGTAAG
CTTACGGCGAATGACCGAATCAGCCT
AGGCTGATTCGGTTCATGCGGATCCA
yDNA (no potential CpG motif)
TGGATCCGCATGACATTCGCCGTAAG
CTTACGGCGAATGACCGAATCAGCCT
AGGCTGATTCGGTTCATGCGGATCCA
Xsmall
GGTATACGGTCAGATCCGTA
TACGGATCTGCGTAGTAGCG
CGCTACTACGGCTAGTACGT
ACGTACTAGCACCGTATACC
VR11
GACAATTCACACACGTCCGCTGGTGGATGGCGCAGTCGGCGACAAATGAGATCGGAAGAGCGTCG
Salmon sperm DNA
Undefined, 100 to 200 bp products
ard screw cap (25 cm2), and 96-well plates with clear bottom and black walls,
• Heidolph (Germany): MR Hei-Standard stirring plate,
• Hellma Analytics (Germany): High Precision Cell 1 mm light path quartz cu-
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Table 2.4: DNA sequences labelled with Cy5.
Cy5-ssDNA
Cy5-TGGATCCGCATGACATTCGCCGTAAGCGACGCTCTTCCGATCTCAT
Cy5-half-dsDNA
Cy5-TGGATCCGCATGACATTCGCCGTAAGCGACGCTCTTCCGATCTCAT
CTTACGGCGAATGACCGAATCAGCCTCGACGCTCTTCCGATCTCAT
Cy5-full-dsDNA
Cy5-TGGATCCGCATGACATTCGCCGTAAGCGACGCTCTTCCGATCTCAT
ATGAGATCGGAAGAGCGTCGCTTACGGCGAATGTCATGCGGATCCA
Cy5-yDNA
Cy5-TGGATCCGCATGACATTCGCCGTAAGCGACGCTCTTCCGATCTCAT
CTTACGGCGAATGACCGAATCAGCCTCGACGCTCTTCCGATCTCAT
AGGCTGATTCGGTTCATGCGGATCCACGACGCTCTTCCGATCTCAT
Table 2.5: DNA sequences of oligonucleotides coupled to 2a.
ssDNA-2a
2a-CTTACGGCGAATGACCGAATCAGCCT
dsDNA-2a
2a-GGCAGCACTGGACACCGACGCTCTTCCGATCTC
2a-GTGTCCAGTGCTGCC
yDNA-2a
2a-TGGATCCGCATGACATTCGCCGTAAG
2a-CTTACGGCGAATGACCGAATCAGCCT
2a-AGGCTGATTCGGTTCATGCGGATCCA
vette,
• Intavis AG (Germany): peptide synthesis 6 mL columns, 5 mL syringes with
filters, and ResPep SL automated solid-phase peptide synthesiser,
• Iris Biotech (Germany): 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC),
N,N -diisopropylethylamine (DIPEA), and N,N’ -diisopropylcarbodiimide (DIC),
Fmoc-L-Trp(Boc)-OH,
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• JPK Intruments AG (Germany): Nanowizard II Atomic Force Microscopy
(AFM),
• Lonza (Switzerland): 1X SYBR Green I and II, and SeaKem LE Agarose,
• Lumiprobe (Germany): Cy5-NHS,
• Martin Christ (Germany): ALPHA 2-4 LD plus lyophiliser and Speedvac ap-
paratus 2-25 CDplus,
• Merck KGaA (Germany): acetonitrile (ACN) (analysis grade), dichlorometh-
ane (DCM), piperidine, trifluoroacetic acid (TFA), triethylamine (TEA), and
sodium dihydrogen phosphate dihydrate (NaH2PO4),
• Merck Millipore (Germany): Milli-Q instrument (Milli-Q Advantage A10) with
a Milli-Q filter LCPAK0001, syringe filters (0.22 µm for aqueous solutions),
heparin sodium salt from porcine intestinal mucosa, Fetal Bovine Serum (FBS),
and O-bis-(aminoethyl)ethylene glycol trityl resin,
• NanoEntek (USA): C-Chip disposable haemocytometers,
• Nunc (USA): cryo tube vials, T25, T75, and T175 cell culture flasks with
standard screw cap (25 cm2),
• Nalgene (USA): cryo freezing container,
• Nanoandmore (Germany): cantilever CP-PNPL-PS-C,
• Nanotemper (Germany): Monolith NT.Automated and standard glass capil-
laries,
• Nanoworld (Switzerland): PNP-TR-Au gold coated silicon nitride AFM probe
(0.08 N m´1),
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• New England BioLabs (USA): purified Bovine Serum Albumin (BSA),
• Plano (Germany): mica,
• Phenomex (USA): Clarity 3u Oligo-RT C18 reverse phase HPLC column,
• Promega (Germany): x-Tracta Gel Extractor,
• Quanta Bio (USA): PerfeCTa SYBR Green SuperMix,
• Raytest (Germany): Stella 3200, and Xstella 1.00 imaging and analysis system,
• Sartorius Stedtim (France): cellulose acetate, polytetrafluoroethylene (PTFE),
polyvinylidenefluoride (PVDF) filters, and filter holder,
• Sigma-Aldrich (USA): acetic anhydride, succinic anhydride, N -hydroxysuccinimide
(NHS), N -hydroxysulfosuccinimide (SNHS), trypan blue solution, 4,5-dimethoxy-
2-nitrobenzyl chloroformate (NVOC-Cl), spermidine trihydrochloride (SpdCl),
Tween 20, acetic acid, Dulbecco’s Modified Eagle’s Medium (DMEM) - high
glucose, boric acid, Ethidium Bromide (EtBr), Cycloheximide (CHX), thiazolyl
blue tetrazolium bromide (MTT), Corning Costar Spin-X centrifuge tube fil-
ters, triethylammonium bicarbonate (TEAB), Actinomycin D (ACT-D), ana-
lytical grade water, and sodium phosphate dibasic heptahydrate (Na2HPO4),
• Th. Geyer (Germany): ACN (purification grade), and triethylammonium acet-
ate (TEAA),
• Thermo Fisher Scientific (Germany): PikoReal Real-Time PCR system with
white 96-well Piko PCR plates and respective optical adhesive films, True-
Start Hot Start Taq DNA Polymerase, NaHCO3, SmaI, EcoRV, dNTP mix,
trypsin/EDTA solution, 15% TBE-Urea Gel, Novex TBE-Urea Sample Buffer
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(2X), TNF-α Recombinant Human Protein, ROX, L-glutamine, 10 and 20 bp
ladders, DNA gel 6X loading dye, and glycogen,
• VACUUBRAND (Germany): vacuum pump RZ6, and PC 3000 series vacuum
controller,
• VWR International (Germany): ethanol, NaCl, NaOH, power source, electro-
phoresis running chambers, 15 mL reaction tubes, peqSTAR2x thermocycler, 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexa-
fluorophosphate (HATU), 1-hydroxy-7-azabenzotriazole (HOAT), HCl, dimethyl-
formamide (DMF), and 96-well plates for cell culture,
• Waters (USA): ACQUITY analytical Ultra-High Performance Liquid Chro-
matography (UHPLC) with UV light detector, the ACQUITY UPLC BEH
analytical reverse phase C18 column (bead size 1.7 µm, 50 ˆ 2.1 mm), AC-
QUITY TQ Electrospray Ionisation Mass Spectroscopy (ESI-MS), analytical
ACQUITY UPLC OST C18 column, e2695 separation module, and 2998 pho-
todiode array detector system,
• Zeiss (Germany): inverted microscope Zeiss Z1 Observer.
2.1.2 General Annealing Protocol of DNA Constructs
The oligonucleotides were diluted in an annealing buffer solution (10 mm Tris-HCl
pH 7.5, 100 mm NaCl, and 1 mm EDTA) and heated for 5 min at 95 ˝C. Then, they
were slowly cooled to room temperature. When indicated, the annealed products
were incubated with 1X SYBR Green I.
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2.2 DNA-Based Diversity Modelling and Analysis
2.2.1 Polymerase Chain Reaction
The PCR amplification was carried in a volume of 50µL on a thermocycler using
the TrueStart Hot Start Taq DNA Polymerase (2 U), with 1.5 mm MgCl2, 150 nm
primers, 0.2 mm dNTP mix, and 100 pm template. The temperature protocol was:
10 min at 95 ˝C (initialisation); five or 25 amplification cycles of 15 s at 95 ˝C (de-
naturation), 30 s at 60 ˝C (annealing), and 20 s at 72 ˝C (elongation); 30 s at 72 ˝C
(final elongation); and 10 s at 20 ˝C (final hold).
Real Time Polymerase Chain Reaction
The RT-PCR experiments were performed using the PerfeCTa SYBR Green Su-
perMix, which has AccuStart Taq DNA polymerase. The amplification reaction was
carried on a PikoReal Real-Time PCR System. When indicated, we used a Mx3000P
RT-PCR system, the associated plates, and ROX. Also when indicated, we used a
homemade version of the RT-PCR mix, which consisted of: 5X TrueStart Hot Start
Taq buffer, 8 mm MgCl2, 0.3 mg mL
´1 BSA, 10% glycerol, 1 U µL´1 TrueStart Hot
Start Taq DNA Polymerase, 1X SYBR Green I, and 400 nm dNTP mix.
Each reaction well had 10µL, with 150 nm primers and 100 pm template. In the
primers concentration titration experiments, the primers A and B1 final concentra-
tion ranged from 500 pm to 500 nm. In the classic AsyPCR experiments, the primer
B1 final concentration ranged from 150 pm to 150 nm. In the template titration
experiments, the DNA template concentration ranged from 1 pm to 10 nm. The tem-
perature protocol was: 10 min at 95 ˝C; 20, 30 or 45 amplification cycles of 15 s at
95 ˝C, 30 s at 60 ˝C, and 20 s at 72 ˝C (data acquisition point); 30 s at 72 ˝C; and 10 s
at 20 ˝C. The results were collected using the PikoReal Software 2.2. All conditions
were performed in triplicate and the results are an average of these values.
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Restriction Enzymes Experiment
The PCR products were prepared as described before and were diluted: ten times for
the five cycles of amplification sample and 100 times for the 25 cycles of amplification
sample. Then, 10 µL of this dilution were incubated with 0.5 µL of a restriction
enzyme, SmaI (10 U µL´1) and/or an isoschizomer of EcoRV (10 U µL´1), for 30 min
at 30 ˝C, 30 min at 37 ˝C and 20 min at 80 ˝C, see Figure 2.1. After, 1 µL of the
digested sample was added to the RT-PCR mix and the amplification was monitored
for 30 cycles.
Figure 2.1: SmaI and EcoRV restriction sites.
Library Diversity Evaluation After a Selection Experiment
The DNA libraries were assembled through annealing in a final concentration of
100 nm. Then, 100µL of 10µm libraries were incubated with 10 µL (1V) SA seph-
arose beads, at room temperature for 1 h in a shaker, in selection buffer (150 mm
NaCl, 25 mm NaHCO3, 0.005% Tween 20, pH 9.2). The SA beads were previously
washed three times with the selection buffer and the beads slurry was resuspended in
selection buffer before being used. After 1 h, the suspension was centrifuged (5 min,
1000 rpm, 4 ˝C) and the supernatant discarded. Following washing steps, one or two,
were performed. The slurry was then subjected to alkaline denaturation (150 nm
NaOH (1V), 3 min at room temperature). Immediately after, the suspension was
acidified with 1.5m acetic acid (0.1V) and again centrifuged. 1µL from the resulting
supernatant was added to the RT-PCR mix and the amplification was monitored for
30 cycles.
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2.2.2 Fluorescence Development Experiment
We monitored the melting curve of annealed products incubated with 1X SYBR
Green I and recorded the interval between 20 and 95 ˝C. S1 was used as the limiting
strand, to normalise the final annealed product amount among all the constructs.
The final melting curve is given as the first derivative of the recorded fluorescence
(RFU), after smoothing with the Savitzky-Golay filter.
2.2.3 Electrophoresis
The gels were imaged on a Stella 3200 and Xstella 1.00 imaging and analysis system.
Unless stated otherwise, the 10 µL RT-PCR reactions were loaded onto each well.
Denaturing Urea Polyacrylamide Gel Electrophoresis
For DNA resolving, 15% TBE-urea gels were pre-ran in 1X Tris/Borate/EDTA
(TBE) buffer (89 mm Tris-borate, 2 mm EDTA, pH 8.4), at 160 V and 10 mA, for
30 min. The amplified samples were directly added 2X TBE Urea Sample Buffer (in
a final volume of 10µm) and heated to 70 ˝C for 3 min. Then, immediately placed on
ice. When extreme denaturation conditions are indicated, a denaturation at 95 ˝C
for 10 min was done instead. The gels ran for 1 h, at 160 V and 10 mA. After the
run, they were read at 470 nm (SYBR Green I signal). When indicated, the gels were
further stained for 20 min with 1X SYBR Green II in 1X TBE.
Agarose Gels
The samples were ran on a 4% agarose gel, which was stained with 1:20,000 EtBr
when indicated. The gel was ran for 1 h, at 80 V in 1X TBE buffer. If the gel was
not stained with EtBr, the SYBR Green I signal was monitored, as indicated.
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2.2.4 Atomic Force Microscopy Imaging
AFM images of the RT-PCR products were deposited on freshly cleaved mica in the
presence of the imaging buffer (300 mm SpdCl, 300 mm NaCl, 20 mm Tris in analytical
grade water) [208]. Optimal dilutions were deposited on the mica and kept still for
90 s. The substrate was then rinsed with analytical grade water and dried with a
steady flow of nitrogen. The images were obtained in air, by contact mode, using a
Nanowizard II. Silicon nitride cantilevers of 200µm length, with a resonant frequency
of about 17 kHz and spring constant of about 0.08 N m´1 with a gold coating were
used. A second order polynomial function was used to remove background slope
and the images are shown as a heat map of the surface’s topography. DNA origami
constructs were imaged as controls to the imaging process. SpdCl is present for the
binding and spreading of ssDNA and dsDNA on the mica surface [209].
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2.3 Physical Environment Regulation of TNF-α Activity
2.3.1 TNF-α
Mouse recombinant TNF-α was the standard protein used in this study. When
indicated, a commercial human recombinant TNF-α was used. Both domestic and
commercial TNF-α bioactivity on L929 cells was tested and it was concluded they
had equivalent values, see Figure 2.2.
Figure 2.2: Cytotoxicity comparison between recombinant mouse and human TNF-
α forms.
TNF-α-Cy5 Each trimer was labelled with 15 equivalents (eq.) Cy5-NHS in 0.1 mm
NaHCO3 pH 8, in a glass vial with a stirrer, for 2 h on ice. Then, the reaction was
quenched with 0.5 mm Tris pH 9 for 20 min, and the product was purified using a
PD10 desalting column.
TNF-α-NVOC Each monomer was labelled with five or 25 eq. NVOC-Cl in 1X PBS
pH 7.5, in a glass vial with a stirrer, for 2 h on ice, protected from light. Then, the
reaction was quenched with 0.5 mm Tris pH 9 for 20 min and the product was purified
using a PD10 desalting column. For the cell assay, the TNF-α-NVOC control was
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kept away from light exposure and the cleaved TNF-α-NVOC was subjected to a
30 min exposure under a 366 nm lamp.
2.3.2 Anti-TNF-α Small Molecules Synthesis
The anti-TNF-α compound 2a (Kd = 50 µm, Figure 2.3a) was synthesised as in
Buller et al. [112], purified by High Performance Liquid Chromatography (HPLC)
and confirmed by Mass Spectrometry (MS) (rM ´ Hs´ “ 437.8;Mcalc “ 439.0).
Compound 2c (Kd = 15µm, Figure 2.3b) was prepared by coupling tryptophan (Trp)
(Figure 2.3c) to 2a. 2a-PEG (rM `Hs` “ 587.0;Mcalc “ 586.0) and 2c-PEG (rM `
Hs` “ 855.0;Mcalc “ 854.0) were prepared on a O-bis-(aminoethyl)ethylene glycol
trityl resin, in DMF. Two eq. Trp (Fmoc-L-Trp(Boc)-OH), 2 eq. HATU and 2 eq.
HOAT were activated for 30 min at room temperature, then added to the resin along
with 6 eq. DIPEA. After, Fmoc was removed with a 20% piperidine solution in DMF
and another reaction mixture was added to the resin, overnight at room temperature,
composed of: 2 eq. 2a, 2 eq. HATU and 2 eq. HOAT. This mixture was activated for
30 min at room temperature and, then, added 6 eq. DIPEA. Considering that the
first coupling with Trp was not 100% efficient, the free amino groups still present in
the resin were able to react with 2a directly, generating 2a-PEG. The amino groups
modified by Trp coupled to 2a and formed 2c. The day after, the resin was cleaved
with 3% TFA in DCM. The final products 2a-PEG and 2c-PEG, which corresponds
to 2a-Trp-PEG, were purified by reverse phase HPLC and identified by analytical
reverse phase UHPLC with a C18 column and ESI-MS.
2.3.3 Oligonucleotides Assembly and Modification
DNA Structures
Several DNA structures based on a previews publication [147] were assembled for
the experiments, see Figures 2.4 and Tables 2.3, 2.4, and 2.5.
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(a) (b) (c)
Figure 2.3: Small molecules 2a (a) and 2c (c) and Trp (c) structures.
In the band-shift and cell assays, the structures were annealed as described above.
For the Circular Dichroism (CD) spectroscopy experiments, the DNA constructs were
annealed in 10 mm sodium phosphate buffer, pH 7.4.
A 10 mg mL´1 S-DNA solution was prepared in 50 mm Tris pH 7.5. S-DNA was
used because it could achieve higher concentrations not possible for synthetic DNA
structures. To ensure an accurate correlation between S-DNA and defined DNA
structures concentrations, we titrated the cytotoxicity of S-DNA from zero to 45ˆ the
optical density at 260 nm (OD260) of a 5 µm two half-complementary strands (half-
dsDNA) annealed product (Figure 2.5), with 0.1 ng mL´1 of TNF-α. For consequent
experiments, it was set that 10ˆ OD260 of S-DNA represented 1ˆ OD260 of half-
dsDNA at 5µm.
DNA Coupling to Anti-TNF-α Small Molecules
The oligonucleotide sequences listed on Table 2.5 were coupled through their free
5’-end amino group to the free carboxylic group present in 2a. Around 100 nm DNA
pellet was solved in a 300 nm TEA/HCl, pH 9 buffer. The carboxylic group in 20 mm
2a was activated with 20 mm NHS and 20 mm DIC for 30 min, at room temperature
on a shaker. Then, DMF and the aqueous solution with DNA were added to the
activated 2a, in a final ratio of 70% DMF to 30% water. This mixture was left
reacting overnight, at room temperature on a shaker.
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(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
(m)
Figure 2.4: DNA structures used in this project: ssDNA (a), half-dsDNA (b),
full-dsDNA (c), yDNA (d), yDNA with a short overhang (e), quadruplex (f), Cy5-
ssDNA (g), Cy5-half-dsDNA (h), Cy5-full-dsDNA (i), Cy5-yDNA (j), 2a-ssDNA (k),
2a-half-dsDNA (l), and 2a-yDNA (m).
On the next day, we performed ethanol precipitation adding 1/10V sodium acetate
and 3V ethanol 100%. The tubes were put at ´80 ˝C for 1 h and then centrifuged
for 30 min, 14 000 rpm at 4 ˝C. The pellet was washed with ethanol 70% and again
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Figure 2.5: S-DNA titration considering 1ˆ OD260 a 5µm half-dsDNA annealed
product. TNF-α concentration was 0.1 ng mL´1.
centrifuged for 30 min, 14 000 rpm at 4 ˝C. Finally, the pellet was air-dried.
TEAA was added to a final concentration of 100 mm, centrifuged for 10 min, at
14 000 rpm and at room temperature. Then, the purification on a reverse phase
HPLC column. Buffer A was 100 mm TEAA in water and buffer B was 100 mm
TEAA in ACN. An elution gradient with buffer B from 5 to 50% for 15 min at
5 mL min´1 was done. Before the gradient started, the column was flushed with
5% buffer B for 4 min. After, the column was flushed with 95% buffer B, with
a fast gradient for 1 min. Then, the column went to the initial condition, with a
gradient from 95 to 5% buffer B. The purification was monitored at 260 nm. The
oligonucleotides were characterised by analytical reverse phase UHPLC with a C18
column and ESI-MS, with an elution gradient from 5 to 95% 50 mm TEAB in ACN
buffer for 5 min at 2 mL min´1. The positively identified samples were dried on the
Speedvac and resuspended in the desired final volume.
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2.3.4 Heparin Modification
Heparin (14 kDa) was acetylated in water with 5% acetic anhydride and 2% TEA,
for 1 h at room temperature. Then, it was precipitated with tetrahydrofuran (THF)
for 20 min at ´20 ˝C and centrifuged for 30 min, 8500 rpm at 4 ˝C. Heparin-2a and
-2c conjugates were prepared by coupling acetylated heparin with 2a- and 2c-PEG.
One eq. acetylated heparin, 10 eq. SNHS, and 6 eq. EDC were activated for 5 min
at room temperature, in phosphate buffer, pH 7.5. Then, 5 eq. 2a- or 2c-PEG were
added. The reaction was left overnight and the coupled product was retrieved by
THF precipitation. The final product identity was confirmed and quantified by the
increased absorbance at 280 nm.
2.3.5 TNF-α Binding to Biopolymers Assays
DNA Band-Shift
The DNA constructs were incubated with TNF-α for 1 h, at 4 ˝C on a shaker and
in selection buffer (100 mm NaCl, 20 mm Tris-HCl pH 7.6, 2 mm MgCl2, 5 mm KCl,
1 mm CaCl2, 0.02% Tween 20). The incubation product then was resolved with a
electrophoresis run on a 4% agarose gel, which was stained with 1:20,000 EtBr when
indicated. The gel was ran for 2 h and 30 min, at 80 V, 4 ˝C and with cold 1X TBE
buffer. If the gel was not stained with EtBr, the Cy5 signal was monitored. The gels
were imaged on a Stella 3200, and Xstella 1.00 imaging and analysis system.
Bio-Layer Interferometry
For the Bio-Layer Interferometry (BLI) assay, anti-penta-His sensors were tested
using 1X PBS with 0.02% Tween 20 as an assay buffer and 10 mm glycine, pH 1.5,
as regeneration buffer, with a 96-well plate, black and non-binding. Then, increasing
concentrations of S-DNA were tested against a constant concentration of TNF-α, in
the following way: baseline for 50 s, loading for 100 s, and dissociation for 100 s.
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The binding of TNF-α to APS versus ARG sensors was tested with 1X PBS with
0.02% Tween 20 as: baseline for 50 s, loading for 300 s, and dissociation for 300 s.
Finally, our method was optimised for the ARG sensors in a setup that can be seen
on Figure 2.6 and consisted of: baseline for 50 s, loading for 600 s, dissociation for
50 s, and regeneration for 300 s. The tested regeneration buffers were 150 mm NaOH
and 10 mm glycine with 2m NaCl, pH 1.5. The final working buffer was 1X PBS with
0.05% Tween 20. Then, two sensors were treated as controls, incubated only with
TNF-α, and two other sensors were treated as test sensors, incubated with TNF-α
plus DNA or heparin, being the plotted results an average of these grouped values.
Each well, on a 384-well plate, had 50 µL of the assigned solution.
Figure 2.6: Scheme of the BLI assay setup. On the left, the negatively charged
sensor binds the positively charged free TNF-α. On the right, TNF-α is trapped by
interacting with the negatively charged S-DNA and binds less to the sensor.
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Microscale Thermophoresis
After a short incubation of 122.5 nm to 250µm TNF-α with 10 nm Cy5-DNA in 1X
PBS with 0.05% Tween 20, the samples were loaded onto Microscale Thermophoresis
(MST) standard glass capillaries. Then, the analysis was done on the red channel,
with MST power 20%, and excitation power 1%, in a Monolith NT.Automated.
2.3.6 TNF-α Cytotoxicity
L929 cells were grown in DMEM supplemented with 2 mm L-glutamine and 10%
(v/v) FBS. The cells were seeded in 96-well plates at 30,000 cell per well, in 100 µL
complete medium for 24 h before the incubation with TNF-α. Varying concentrations
of recombinant mouse TNF-α were pre-incubated for 30 min at room temperature
with several testing structures (e.g., DNA, heparin) in media containing 8µm CHX.
After, all medium was removed and 90 µL of each test condition was distributed
through the wells. Then, the cells were incubated for 24 h at 37 ˝C and 5% CO2.
On the next day, a solution of MTT in 1X PBS was added to each well to a final
concentration of 0.5 mg mL´1 and incubated for another 90 min at 37 ˝C, 5% CO2.
Finally, all medium was removed and 1V dimethyl sulfoxide (DMSO) was used to
solubilise the formazan crystals. Their absorbance was read at 540 nm. Cell viability
(CV) was calculated as,
CV p%q “
X ´B
C ´B
ˆ 100
Where B is the blank (wells only with medium), C is the control (wells with
medium plus CHX) and X is the absorbance from the test wells.
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2.3.7 TNF-α Structural Changes Monitoring
Circular Dichroism Spectroscopy
CD spectroscopy measurements were performed at 25 ˝C, after incubation of DNA
with TNF-α in 10 mm sodium phosphate buffer, pH 7.4, for 60 min. The data was
collected in the interval from 190 to 260 nm and the final spectra were an average of
five scans.
The DNA spectra were collected alone. Then, a highly concentrated TNF-α solution
was added directly to the 1 mm cuvette, followed by stern shaking. TNF-α and
DNA interaction was monitored at 0, 30 and 60 min. The quantification of TNF-α’s
α-helix was done at 208 and 222 nm, and β-sheet at 217 nm [192].
Homoquenching
The incubation of 2 µm TNF-α with 10 nm TNF-α-Cy5 and 2µm S-DNA during
120 min was done in a 384-well plate, with clear bottom and black walls. Each well
had 80 µL for each tested condition and the working buffer was 1X PBS. The Cy5
signal was monitored and registered as an average of three replicates between 640
and 670 nm, with 150 gain on a Synergy H1 Multi-Mode reader.
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Results
3.1 DNA-Based Diversity Modelling and Analysis
3.1.1 Diversity Analysis
Library Settings The oligonucleotide sequences used in this project are summarised
on Tables 2.1 and 2.2, and illustrated on Figure 3.1. The standard DNA templates
were 60 nucleotides-long, with the first 20 (A; forward primer region) and last 20 (B;
reverse primer region) nucleotides being consistent in all sequences. In the templates
middle region, there was a segment named X, which varied according to what is
described below:
• aptamer libraries: 20 nucleotides that possess from two to 20 randomised pos-
itions,
• high diversity libraries: at least 15 out of 20 nucleotides were different from
each other,
• S1 mismatched complementary templates: a complementary sequence of S 11,
Sx, was increasingly degenerated, from two to 20 mismatches,
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• randomised regions libraries: randomised nucleotides were distributed in every
other position (X2{10), two every two positions (X4{5), and in two groups of five
intercalated with constant nucleotides (X10{2),
• and restriction sites libraries: the six nucleotides in the middle carried the
restriction sites, for EcoRV (XEcoRV ) and SmaI (XSmaI), and were surrounded
by randomised positions.
There were also some structural variations in the primers design:
• for the non-classic asymmetric experiment, forward primers with shorter lengths:
A18, A15, and A12,
• for the allele-specific experiment, primers with extra nucleotides: A20`1, A20`5,
and A20`10,
• and for the experiments with longer primers, primers with ten nucleotides-long
5’-overhang: A10`20 and B10`20.
Diverse Libraries
Diverse libraries from two to 20 randomised nucleotides were screened, see Figure
3.2. The library X2, with 4
2 sequences, had an amplification curve similar to the
standard curves where only one template is used. The sigmoid-shaped curve for lower
diversity samples kept its overall trace, only lowering the plateau of final fluorescence
value until the X8 library. From X10 to X20, the curve became bell-shaped, reaching
a maximum value of fluorescence and decreasing to almost zero.
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Figure 3.1: DNA sequences schematics.
Figure 3.2: RT-PCR experiment using DNA libraries of different diversities (from
two to 20 random positions) as templates.
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The DNA templates were titrated from 1 pm to 10 nm and the curves’ shapes were
consistent for all concentrations and templates. There were only shifts proportional
to the templates’ initial concentration, see Figure 3.3. This demonstrates that the
different curves shape were not affected by templates’ concentration in any of the
libraries tested, S1, X10, and X20.
(a) (b)
(c)
Figure 3.3: Library titration from 1 pm to 10 nm for S1 (a), X10 (b), and X20 (c).
55
Primers Titration
Standard PCR protocols use high concentrations of primers to assure robust amplific-
ation. We worked inside a range where primer concentrations had a linear correlation
with the fluorescence signal. Also, we wanted to verify that this curves’ effect was
not influenced or was an artefact of concentration. Both primers concentration was
titrated from 500 pm to 500 nm (Figure 3.4). As expected, due to the decreased con-
centration, the fluorescence signal had a strong drop linked to lower primer amounts.
We have chosen 100 nm primer concentration for the following experiments because
it is within the range where primer concentrations are correlated linearly with the
fluorescence signal.
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(a) (b)
(c) (d)
Figure 3.4: Forward (A) and reverse (B1) primers titration for S1 (a), X2 (b), X10
(c), and X20 (d) libraries, with final concentrations ranging from 500 pm to 500 nm
for both primers.
Annealing Step Manipulation
To better understand how our system was working and how it could be manipulated,
we checked the influence of the annealing step. The annealing step seemed to be a
good place to start to comprehend in more detail the amplification dynamics of
diverse libraries. The standard annealing step was 30 s, at 60 ˝C and 7 ˝C s´1.
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Annealing Time For all templates tested, S1, X10 and X20, when the annealing step
was 60 s long, amplification process was faster than the 30 s long experiment (Figure
3.5). Moreover, the amplification curve shape was kept.
(a) (b)
(c)
Figure 3.5: Annealing time of 30 s versus 60 s for S1 (a), X10 (b), and X20 (c).
Annealing Temperature For X2, X10 and X20, the lower annealing temperature of
51 ˝C generated lower fluorescence signals and there was a shift in the amplification
course (Figure 3.6). There was less amplified product at this temperature, than at
60 ˝C, because amplification became less efficient. The curves shapes were main-
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tained.
(a) (b)
(c)
Figure 3.6: Testing annealing temperatures of 51 ˝C versus 60 ˝C for X2 (a), X10
(b), and X20 (c).
Annealing Speed When the annealing speed was lower, S1 reached a higher fluores-
cence plateau than at a slightly faster speed (Figure 3.7). However, this effect was
not seen for X10 and was even inverted for X20. The amplification curves kept the
same shape.
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(a) (b)
(c)
Figure 3.7: Annealing speed testing of 7 ˝C s´1 versus 3 ˝C s´1 for S1 (a), X10 (b),
and X20 (c).
Although the course could be slightly affected by annealing time, temperature, or
speed, the correlation between curve shape and library diversity remained unchanged.
Fluorescence Development
The fluorescence development in these experiments was hypothesised to being related
to the formation of increasingly not fully complementary duplexes in a partially
degenerated library. As schematised on Figure 3.8, in initial PCR cycles, DNA
duplexes are fully complementary because they are generated by DNA polymerase.
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The fluorescent dye has higher affinity for duplexes and intercalates it perfectly, so
double strands have a maximum fluorescence value of functional factor (F), which is
assigned to 1.0. In later PCR cycles, the DNA double strands become more and more
mismatched, meaning that the fluorescent dye has progressively less affinity for DNA.
F becomes smaller than one (path 2). This fluorescence development process was
also simulated mathematically (Figure 3.9) and it fitted the experimentally obtained
results.
Figure 3.8: Formation of fully complimentary duplexes during the initial PCR
cycles (1) and mismatched duplexes in later PCR cycles (2). The mismatched du-
plexes have lower F factor and lower affinity to fluorescence dye (green star) at high
temperatures (e.g., 72 ˝C of elongation temperature).
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Figure 3.9: PCR amplification simulation with theoretical DNA libraries of differ-
ent diversities.
This phenomenon was tested using S1 mismatched complementary templates, see
Table 2.1. Eleven annealed products were prepared: from a fully complementary se-
quence, S1 with S1’, to a completely mismatched construct, S1 with S1’M20. A´X´B
and A1 ´ X 1 ´ B1 quick annealing generated mismatched duplexes that were less
stable at 72 ˝C, which corresponds to the elongation temperature in PCR amplific-
ation. This lower double strand stability caused weaker dye binding, lower melting
temperatures, thus, lower fluorescence, see Figure 3.10. One can observe a decreasing
trend in melting temperature and fluorescence intensity from the most stable DNA
duplex, which was fully complementary, to the less stable, with 20 mismatches.
Single-stranded S1 and 1X SYBR Green I showed very low to no fluorescence in the
recorded interval. The melting curves mirrored the trend observed in the first diverse
libraries experiment, see Figure 3.2. The sample S1 with its complementary presen-
ted the highest melting temperature of the tested samples, provided by the highest
number of matches. Then, S1 with two or four mismatches had a similar melting
profile. After, six, eight, ten, 12, 14, 16, 18, and 20 mismatches showed gradually
lower melting temperatures. We observed that fluorescence intensity and melting
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temperature are negatively correlated with the sequence mismatching, even when
there was the same amount of DNA duplexes, as it had been observed by Schuetze
et al. [56].
Figure 3.10: Savitzky-Golay filter smoothing of the first derivatives of mismatched
libraries melting curves. The results correspond to a final concentration of 100 nm
annealed products that were incubated with 1X SYBR Green I. The results shown
are an average of three values.
Templates with Discrete Randomised Regions
Mathematically, X10, X10{2, X4{5, and X2{10 libraries have the same diversity of
410 different sequences, but the randomised nucleotides are distributed differently
(Table 2.2). As compared to X10, we could demonstrate that X10{2, X4{5 and X2{10
had similar amplification curves, even though the degenerated segments are disposed
very differently, see Figure 3.11. For any given library Xn, when n is larger than 16,
each sequence in a 10µL 1 nm sample is statistically unique. But, each sequence in
the randomised regions template is represented several thousands of times. X20, X18,
X16, X2{10, and X4{5 have 18 to 20 nucleotides-long randomisations, and the higher
diversity libraries have curves very different from the medium diversity ones.
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Figure 3.11: RT-PCR experiments using different libraries of same diversity. X10,
X10{2, X2{10, and X4{5 have the same diversity, but different distribution of partially
degenerated segments inside the sequence.
High Diversity Templates
The high diversity templates were designed so, at least, 15 out of 20 nucleotides in the
X region would be different. This design is in contrast with X20, for example, where
the difference between two sequences can range from zero to 20. This new highly
diverse library contains n sub-libraries, where members of each library are identical
and the difference between sub-libraries is very high. To test the binding properties
of fully matched and mismatched sequences to the dye, two annealed products were
prepared: S1 with S1’, a fully complementary duplex; and S10 with S1’, a highly
mismatched duplex, with only four matches (Figure 3.12). Then, an agarose gel was
ran. The annealed product 1 had a stronger band intensity than the product 2,
which showed a higher amount of fully complementary product over the mismatched
one.
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Figure 3.12: The correct annealed product is 60 bp: S1 annealed with S1’ (1) and
S10 annealed with S1’ (2). 1 µm annealed DNA in a 4% agarose gel stained with 1X
SYBR Green I with a 20 bp DNA ladder.
We then proceeded to the amplification curves monitoring, see Figure 3.13. Only
one sequence template generated a sigmoidal curve with fluorescence signal higher
than the two templates mixture at the plateau phase. Further mixing with high
diversity templates was done, from two to ten, and the fluorescence signal emulated
what happened to the partially degenerated libraries with diversities up to X8 (4
8
different sequences). For the ten sequences mix, the fluorescence at the plateau
decreased to half value of the maximum reached with one sequence.
The fluorescence signal development was influenced by the templates diversity and
not the number of members present, because a mix of ten high diversity sequences,
with, at least, 15 out of 20 different nucleotides, had the same amplification behaviour
as an aptamer library with 65,536 sequences, with zero to eight nucleotides possibly
different.
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Figure 3.13: RT-PCR experiment using a small number of highly diverse sequences,
where sequences have been designed to have a large difference (more than 15) between
themselves.
3.1.2 Libraries Manipulation Through Primer Design
The standard amplification was done using 20 nucleotides-long primers, A and B1,
which created 60 bp products. In this section, we explore the impact of primers
length, sequence and concentration imbalance on the amplification behaviour for the
different templates.
Longer Primers
To understand if the amplification behaviour would be the same for a longer template
using longer priming regions, with higher melting temperatures, we designed 30
nucleotide-long primers, A10`20 andB
1
10`20. This way, the newly formed DNA strands
were 80 bp (Figure 3.14). As expected, longer amplified products yielded higher
fluorescence values, which was seen for S1, X16 and X20. Interestingly, for X16 and
X20, the fluorescence after the peak did not go as low as in the 60 bp control, altering
the curves’ shapes.
With longer primers, the resulting duplexes are more stable. Thus, their binding to
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the fluorescent dye at an elevated temperature is less affected by mismatching.
(a) (b)
(c)
Figure 3.14: Amplification curves for S1 (a), X16 (b), and X20 (c) while using 30
nucleotide-long primers.
Classic Asymmetric PCR
As PCR amplification is a process of population growth, the two primers needed
can be seen as pivotal resources. Being these two resources inter-dependent, the
limitation of only one can be detrimental to population growth. Classic AsyPCR is
a common protocol for ssDNA generation and it is based on the imbalance of primer
concentration. One primer is in excess in relation to the other, so one strand is
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preferentially amplified [30]. In this experiment, we wanted to observe how primer
imbalance could affect the amplification of diverse libraries.
For the S1 and X20 templates, the decreased primer B
1 concentrations led to a lower
molarity of the system, which generated lower fluorescence. The amplification was
only efficient when B1 concentration was ten times lower, 15 nm. For 1.5 nm and
150 pm, the amplification could not be detected, see Figure 3.15. The amplification
was directed by the consumption of one primer, or lack thereof, hampering the
comparison between libraries of different multiplicity. Further conditions were tested,
from 500 nm to 500 pm. In all conditions, the amplification behaviour was only similar
to the standard conditions down to ten times less B1 (Figure 3.16).
(a) (b)
Figure 3.15: Classic AsyPCR amplification curves for S1 (a) and X20 (b). A was
in 150 nm final concentration, while B1 concentration ranged from 150 pm to 150 nm.
Non-Classic Asymmetric PCR
We then designed a AsyPCR experiment using primers with shorter lengths [29].
Thus, the new shorter A had lower annealing temperature. When combining it with
the full-length B1, the polymerisation started by shorter primers was the rate-limiting
step. The primers inefficiency was then linked to their length, A18, A15 and A12 (Fig-
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(a) (b)
(c) (d)
Figure 3.16: Classic AsyPCR amplification curves for S1 (a), X2 (b), X10 (c), and
X20 (d). A was in 150 nm final concentration, while B
1 concentration ranged from
500 pm to 500 nm.
ure 3.17). In all libraries tested, S1, X10 and X20, the amplification with A18 was
similar to the full-length A, only with lower fluorescence values. Probably because
the amplified product was shorter by two nucleotides, leading to lower fluorescence.
When A15 was used, amplification was possible. With A12, there was no amplifica-
tion in every condition.
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(a) (b)
(c)
Figure 3.17: RT-PCR using two primers of same or different length (B1 with A,
A18, A15 or A12) using S1 (a), X10 (b), or X20 (c) as templates.
In parallel, we simulated this setup with synthetic data and the results obtained
were very similar to the experimental data (Figure 3.18). For one sequence, medium
and large libraries, when the primer became ten times less efficient, the amplification
was kept, but with reduced amplification rates. When the primers were only 1%
efficient, the amplifications were remarkably suppressed. The simulation anticipated
that the fluorescence peak would be delayed and with lower F. The synthesis of
perfect matched duplexes became slower. So, the resulting increase of fluorescence
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was overcome by the counter effect associated with DNA reshuffling at lower full
length DNA concentration. This effect was particularly strong for the high diversity
library.
(a) (b)
(c)
Figure 3.18: Simulation of amplification curves of one sequence (d), medium library
(e), and large library (f), where amplification efficacy goes from 1 to 100%.
We further imaged the products of this asymmetric amplification (Figure 3.19).
SYBR green I binds preferentially to dsDNA, while SYBR green II binds to both
ssDNA and dsDNA. Therefore, the difference between these two staining method
reflects the ratio between single and double stranded DNA. Consistent with the
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amplification curves, after 20 cycles, A and A18 generated similarly correct size DNA,
which could be stained by both SYBR Green I and II. While A15 and A12 were
unable to generate detectable signal. Interestingly, when A15 concentration was
doubled, there was some ssDNA at 60 bp being amplified. After 40 cycles, A and
A18 generated some products, with higher to much higher molecular weights then
the template, creating a smear. A15 generated a 60 bp product, and when in double
concentration, it generated also extra products with heavier molecular weight. A12
continued to not be able to carry on the amplification.
Figure 3.19: RT-PCR using primers of same or different length (B1 with A, A18,
A15, A12, twice A15, or twice A12) using S1 as template. On the left, there is the 1X
SYBR Green I signal, which has more affinity to dsDNA and on the right there is
the 1X SYBR Green II signal, which has more affinity to ssDNA. 10 bp DNA ladder,
15% TBE-urea gel.
Biased Population Growth
The next step in our investigation was to go in the opposite direction and use longer
versions ofA, in order to bias the DNA amplification in a sequence-controlled manner,
just as in AS-PCR [33]. Using the principles of AS-PCR, we designed an experiment
where we could manipulate and pick sequences that followed rules imposed by the
primers from diverse libraries (Figures 3.20 and 3.21).
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(a) (b)
(c) (d)
(e) (f)
Figure 3.20: Screening of population growth manipulation using A, A20`1, A20`5
or A20`10 as a primer with the libraries X2 (a), X4 (b), X6 (c), X8 (d), X10 (e), and
X12 (f).
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(a) (b)
(c) (d)
Figure 3.21: Screening of population growth manipulation using A, A20`1, A20`5
or A20`10 as a primer with the libraries X14 (a), X16 (b), X18 (c), and X20 (d)
(continuation).
When A was employed in X20 amplification, every template was amplified, so
diversity was 420. A20`1, A20`5, and A20`10 selectively annealed to and amplified
1/4, 1{45, and 1{410 of X20, respectively. This resulted in products of decreased
diversity, see Figure 3.21d. A20`1 shifted the amplification curve to the right (4
19
templates) and A20`5 caused a greater shift because it only amplified templates which
had ATTCG after the priming region (415 templates). The diversity of both libraries
was still high, so the end fluorescence signal remained similar. When A20`10 was used
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with X20, on top of the farther right shift, the curve shape became similar to the
one obtained for X10. The diversity of 4
20 went down to 410 (Figure 3.22b). In X10,
the allele-specific primers from A to A20`5 caused no difference because the same
library members were amplified in every condition (Figure 3.20e). For X18, A20`1
did not cause a shift because the primer matched all sequences (Figure 3.21c). When
X10{2 was amplified with A20`1 and A20`5, the diversities were reduced from 4
10 to
49 and 45, respectively, transforming its amplification curve from a bell shape to a
sigmoid (Figure 3.22a). The biased amplification could be detected by a right-shift
(influenced by concentration) and curve-shape (influenced by diversity).
(a) (b)
Figure 3.22: Comparison of biased population growth using A, A20`1, A20`5 or
A20`10 as a primer with the libraries X10{2 (a) and X20 (b).
3.1.3 Protection by Population Diversity
Following the AS-PCR experiments, we wanted to understand how far the librar-
ies diversity could be manipulated. For that end, we planned an experiment that
would use the diversity as a selection/protection factor and that could be handled
specifically. The libraries XEcoRV and XSmaI (Table 2.2) carried the restriction sites
for EcoRV and SmaI, respectively. Both are endonucleases that create blunt ends
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(Figure 2.1), and only recognise duplex restriction sites. This experiment relied on
the fully-matched early duplexes as perfect restriction sites (early cycles); thus, there
will be digestion. After, the progressively mismatched duplexes (later cycles) gener-
ate lower to no digestion (Figure 3.23). The restriction sites function as a selection
mechanism.
Figure 3.23: Diversity of libraries with restriction sites has a protective effect
against endonuclease action. The fully complimentary duplex synthesised in the
initial PCR cycles is more sensitive to endonucleases than the mismatched duplex
generated in the late PCR cycles.
Restriction Enzymes Activity Check To verify that the libraries carrying the restric-
tion sites were recognised and digested by the proper enzymes, we incubated 15
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cycles PCR amplified product of libraries (XSmaI , XEcoRV , X20) with SmaI or EcoRV
(Figure 3.24). XSmaI and XEcoRV were successfully digested by SmaI and EcoRV,
respectively, originating a product of around 30 bp, and there was significantly less
60 bp original template. X20 was used as a control of no digestion.
Figure 3.24: XSmaI incubated with SmaI (1) and no enzyme control (2), XEcoRV
incubated with EcoRV (3) and no enzyme control (4), and X20 incubated with SmaI
(5) and no enzyme control (6). 10µL of PCR product treated with endonucleases
were loaded into the gel. 20 bp ladder, 4% agarose gel with EtBr.
Amplification Curves The libraries were subjected to five or 25 cycles of amplification.
Then, a diluted aliquot was treated with SmaI and/or EcoRV. After five cycles,
most of all of newly synthesised DNA was in a perfect matched duplex and the fully
complementary duplexes were recognised by the enzymes and digested, see Figure
3.25. There was a shift of around three cycles, in comparison to the no enzyme
control, when one of the enzymes was used. When both enzymes were used, this
shift was around seven cycles. When the population was amplified for 25 cycles,
the mismatched population protected itself from digestion, because the restriction
sites were not in a duplex and, thus, were not recognised. As a result, all conditions
had the same amount of DNA template and the curves could not be distinguished.
DNA reshuffling generated a heterogenous population that protected the templates
from endonuclease digestion. The fully complimentary duplex synthesised in the
initial PCR cycles was more sensitive to endonucleases than the mismatched duplex
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generated in later PCR cycles.
(a) (b)
Figure 3.25: Amplification curves of the mixture of XSmaI and XEcoRV pre-treated
for five (a) and 25 (b) PCR cycles and after incubation with SmaI and/or EcoRV.
Electrophoresis To further demonstrate that diversity provides protection, we treated
20 and 35 cycles of amplification RT-PCR products of XSmaI , XEcoRV and S1 with
SmaI, and ran an agarose gel (Figure 3.26). SmaI was not able to digest any of the
amplified products, meaning that 20 cycles was already too late for perfect matching.
After 35 cycles of amplification, we saw a distribution of higher molecular weight
products. This observation fits the fluorescence seen on Figure 3.25b, where there
was an unexpected reoccurrence of fluorescence after 20 RT-PCR cycles on top of 25
PCR cycles of amplification. This phenomenon is discussed in the next section.
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Figure 3.26: RT-PCR products treated with SmaI after 20 (a) and 35 cycles of
amplification (b). 20 bp ladder, 4% agarose gel with 1X SYBR Green I.
3.1.4 High-Entropy Structures Formation
The later cycles of the amplification generated structures which had higher affinity
to SYBR Green I, enhancing the fluorescence of the RT-PCR amplification curve to
levels that were not correlated to the concentration of the DNA present in solution.
We hypothesised that the large diversity of random templates gave space to unex-
pected interactions, which generated structures other than duplexes. For instance,
X20 could create interactions that would go beyond the power of computation. So, a
highly diverse DNA library had more probability of evolving into complex structures
than a non-diverse library.
The first observation of this effect was after the 25 times PCR amplified sample, for
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the endonuclease experiment, generated fluorescence values higher than the maximal
fluorescent signal observed in standard RT-PCR experiments. Without the pre-PCR
treatment, the fluorescence increase was only observed after 37 cycles. The initial
fluorescence decrease we perceived was caused by lower dye affinity to less stable mis-
matched DNA duplexes, but the increase at later stages was probably caused by the
enhanced dye affinity for highly convoluted and complex structures and networks.
To understand how these structures are structured, we imaged them with agarose
gel electrophoresis and AFM.
Temperature Effect
These ultra-structures were formed later when the handling occurred at 4 ˝C (37
cycles) and earlier if at 25 ˝C (32 cycles) (Figure 3.27). After, the samples obtained
in these conditions were ran in an agarose gel, see Figure 3.28. It can be seen that the
4 ˝C condition generated several bands corresponding to higher molecular weights,
heavier than 60 bp. At 25 ˝C, there were no clear bands, only smears of undefined
DNA products. This observation suggests that the structures formed at 25 ˝C were
too complex to be separated on an agarose gel.
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(a) (b)
Figure 3.27: Amplification of S1, X2, X6, X16, and X20 during 45 cycles, with
handling at 4 ˝C (a) and at 30 ˝C (b).
Figure 3.28: RT-PCR products amplified for 45 cycles at 4 ˝C (a) and 25 ˝C (b).
The correct 60 bp product corresponds to the lowest molecular weight band. 4%
agarose gel with 1X SYBR Green I.
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Amplified Products Electrophoresis
To determine in more detail the structures being formed at room temperature, we
further tested our samples in different conditions using electrophoresis.
Agarose Gels Samples collected after 20, 35, and 45 cycles of amplification for S1,
X16, and X20 were ran in an agarose gel (Figure 3.29). After 20 cycles, S1 had a
strong band of the correct molecular weight DNA, 60 bp. The same was seen for the
other libraries, with only a faint extra band at 80 bp. After 35 cycles, S1 had also a
faint extra band at 80 bp, while X16 and X20 showed more bands above 80 bp. After
45 cycles, all samples showed several extra bands above 60 bp.
Figure 3.29: DNA samples of different diversity (S1, X16, and X20) were subjected
to 20 (a), 35 (b), or 45 (c) cycles. The correct amplified product corresponds to the
band with the lowest molecular weight, 60 bp. 4% agarose gel with 1X SYBR Green
I.
TBE-Urea Gels For a more detailed analysis, we prepared differently amplified samples
and analysed them by Polyacrylamide Gel Electrophoresis (PAGE) under denatur-
ing conditions. On Figure 3.30, after 20 cycles, there were still a lot of primers
not consumed (20 bp) and the correct size final product (60 bp) had only a faint
band. While ssDNA showed only one band, the dsDNA PCR product showed two
bands, indicating the duplex was not fully denatured. Bands corresponding to DNA
larger than 60 bp were observed in X16 and X20, but not in the sample with only
one sequence (S1) with X16 presenting the largest shift. After 45 cycles, the 20 bp
82
band diminished and the 60 bp increased intensity. High molecular weight bands
appeared in all samples, though S1 still produced a strong 60 bp band. Then, higher
molecular weight bands were developed up to a complete smear for the DNA sample
with higher diversity, X20. A similar gel was run with PCR samples that had been
denatured for the double amount of time and at a higher temperature, see Figure
3.31. The results were similar, but the resolution was improved, because the dsDNA
was denatured more completely.
Figure 3.30: DNA samples of different diversity (S1, X2, X16, and X20) were
subjected to 20 or 45 PCR cycles, and separated under denaturing conditions. 5µL
of PCR product were loaded into the gel. 10 bp ladder, 15% TBE-urea gel with 1X
SYBR Green II.
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Figure 3.31: DNA samples of different diversity (S1, X16, and X20) were subjected
to none, 15, 20, or 45 PCR cycles, denatured under extreme conditions, and separated
on a denaturing gel. 5µL of PCR product were loaded into the gel. 10 bp ladder,
15% TBE-urea gel with 1X SYBR Green II.
On the next gel electrophoresis experiment, we monitored the dsDNA (SYBR
Green I) and ssDNA (SYBR Green II) signals, see Figure 3.32. The dsDNA could
not be seen after 15 cycles of amplification because it had been denatured by urea
completely. However, it could be seen with SYBR Green II staining. After 20 cycles
of amplification, the product became more stable and more difficult to break. For
higher diversity libraries, there was an increased amount of bands corresponding
to higher molecular weights. The ssDNA staining using SYBR Green II was also
interesting, because it also became heavier according to the diversity of the original
sample. After 45 cycles of amplification, the correct product became less visible and
bands corresponding to higher molecular weight DNA were predominant.
It is important to note that the decrease of overall signal intensity did not reflect the
loss of sample. It shows the increase of length heterogeneity, which could no longer
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be resolved by gel electrophoresis.
Figure 3.32: DNA samples of different diversity (S1, X10, X14, X16, and X20) were
subjected to 15, 20, or 45 PCR cycles, and separated on a denaturing gel. 1X SYBR
Green I shows the dsDNA (a) and 1X SYBR Green II shows the ssDNA (b) signals.
5 µL of RT-PCR product were loaded into the gel. 10 bp ladder, 15% TBE-urea gel.
Atomic Force Microscopy Imaging
The RT-PCR products were also imaged by topographic analyses on the AFM, see
Figure 3.33. The correct 60 bp product corresponds to around 20 nm structures,
showing as a dot in the provided conditions. The height of ssDNA is around 0.4 to
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0.6 nm and dsDNA’s from 0.8 to 1.2 nm.
After 20 cycles, S1’s height was consistent with dsDNA and the length was around
20 nm, with some longer structures. Small structures of dsDNA were mainly observed
for both S1 and X20. After 45 cycles, the dots became larger and thicker. Mostly
large structures were detected for X12, X14, X16, and X20, but not S1. Structures
higher than standard DNA duplex were seen, especially for X16. After 20 cycles, X20
generated DNA structures that were longer and higher than the ones of S1. After
45 cycles, superstructures much higher and longer than dsDNA were observed. The
prolonged PCR amplification of diverse DNA libraries led to complex 3D structures,
as can be confirmed on Figure 3.34. DNA origami was used as a control for assay
development. Freezing and thawing samples induced structural changes, mainly
clumping (Figure 3.35).
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Figure 3.33: AFM analyses of RT-PCR products of S1 after 20 (a) and 45 cycles
(b), X20 after 20 cycles (c), and 45 cycles of amplification (d). Images are 1 µm ˆ
1 µm and the scale bar is 250 nm.
Figure 3.34: AFM analyses of RT-PCR products of X12 (a), X14 (b), and X16 (c)
after 45 cycles of amplification. Images are 1µm ˆ 1 µm and the scale bar is 250 nm.
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Figure 3.35: Frozen and thawed treated RT-PCR sample of S1 after 45 cycles of
amplification (a). Stiff in air tapping of DNA origami controls (b).
3.1.5 Library Diversity Evaluation After Selection
To emulate a real selection, we used ten highly diverse sequences (from S1 to S10)
and the B1 primer. This construct had a melting temperature around 54 ˝C s´1. B1
was modified with biotin (a high affinity binder to SA), iminobiotin (a weak binder),
or was not modified at all (Figures 3.36a and 3.36b). Using these constructs, we
created four different libraries: LibA, which consisted of S1 annealed with a biotin-
primer and S2 to S10 annealed to an unmodified primer (with some strong binders);
LibB, which was the same as LibA, but with an iminobiotin-primer (with some
weak binders); LibC, where S1 to S10 were annealed to the iminobiotin-primer (with
many weak binders); and LibD, where S1 was annealed to biotin-primer and S2 to
S10 were annealed to the iminobiotin-primer (with some strong binders, but mostly
weak). These libraries were incubated with SA beads. The beads were washed, once
or twice to mimic different selection stringencies, and the solution pH was increased
and then decreased so the DNA templates would be in solution to further continue
with RT-PCR monitoring.
Figure 3.36c is the result of the selection experiment after washing the SA beads
once and Figure 3.36d twice. In both graphs, LibA has a sigmoid amplification
curve compatible with the existence of one template, or a very low diversity sample.
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In LibA, only S1 is annealed to the biotin-primer, so only this template was able to
bind to SA. The extra wash did not alter the outcome for this library. LibB was
the least enriched condition and the difference between one or two washes was clear.
After one wash, the S1-iminobiotin construct was still present in the final solution,
but after two washes, this construct was in lower amount. Thus, the shifted curve to
the right. Removing unspecific binding of unmodified DNA increased the end-point
value. Since iminobiotin has lower Kd than biotin, this result fit our expectation and
the increase of 5.6 amplification cycles was caused by this. With LibC, there was a
stark decrease in the fluorescence plateau, reflecting the larger diversity of the pool
monitored, because all ten sequences were present.
After a second wash, a mixture of different constructs remained. For LibD, even
though the curve shape was similar to LibA, there was a lower fluorescence value at
the plateau for after one wash. More DNA in LibD bound to the SA beads than
the other libraries, because all constructs were modified with either strong or weak
binders. After two washes, iminobiotin constructs were washed out, producing lower
diversity. Interestingly, after one wash, its end-point was lower than LibA, indicating
that the selection using LibD generated a mixture of compounds, even though the
strong affinity compound was the major participant. After the second wash, only
one construct was dominant. The stringency simulation demonstrated that with
more stringent selection conditions, as in two washing steps, LibB and LibD curves
indicated only one major binder, whereas LibC curve, which was composed of many
compounds of similar affinity, was not altered.
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(a) (b)
(c) (d)
Figure 3.36: Libraries schematic (a): ten sequences (see Table 2.1) were annealed
with a 20-mer sequence (B1) (b), which was modified with biotin (full dot), imino-
biotin (empty dot), or unmodified (dash). The selected mixture on SA beads after
one (c) and two washing steps (d) was eluted and subjected to RT-PCR for diversity
evaluation.
3.1.6 Controls
To ensure that the DDMA was robust and reproducible, we tested several control
conditions.
Other Machine Another RT-PCR instrument was used to verify that our findings
were not dependent on our system. The instrument used was a Mx3000P system
and was ROX-dependent. ROX is used as a reference in ROX-dependent RT-PCR
instruments. It does not interfere with the amplification, is not correlated with
DNA concentration, is constant among wells, and normalises fluorescence variations
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in optical paths. The constant ROX value integrated with the fluorescent reporter
used normalises wells’ fluorescence [47]. We tested our system’s reproducibility after
adding ROX and there was no interference, see Figure 3.37a. Then, we proceeded
to amplification on the Mx3000P system and the results were similar to the ones
obtained with the PikoReal system. The only difference was the range of fluorescence
values, which were around five times higher with the new system (Figure 3.37b).
Other Master Mix To verify that the effect we described was also not dependent on
the commercial master mix used, we prepared a homemade version. Once again, the
amplification pattern was similar, and the only difference was on the fluorescence
signal, which was higher for the commercial master mix (Figure 3.37c).
Other Library To finally address the question if this phenomenon was sequence de-
pendent, another DNA diverse library, Y20, was tested (Table 2.2). This library also
had 20 randomised positions and the forward (C) and reverse (D1) primers were 23
nucleotides-long, so the final DNA amplified product was of 66 bp. The amplification
curve for Y20 was also shaped as a bell curve, but the maximum fluorescence value
was lower than the one of X20, see Figure 3.37d.
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(a) (b)
(c) (d)
Figure 3.37: The addition of ROX did not alter the amplification and thereof
fluorescence of the templates (a). Amplification curves obtained using another in-
strument (b). Comparison between commercial and homemade master mixes (c).
Amplification curve obtained for another diverse library compared to the standard
library used in this project (d).
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3.2 Physical Environment Regulation of TNF-α Activity
3.2.1 Binding Assays
Band-Shift Assays
Unexpectedly, in the search of an improved DNA binding scaffold to TNF-α, all DNA
structures tested (Tables 2.3 and 2.4, and Figure 2.4) were found to bind to TNF-α
with micro-molar affinity (Figure 3.38). Various DNA constructs were incubated
with a large excess of TNF-α for 1 h. Then, a band-shift assay was performed and
DNA bound to it in high extent. An explanation for this effect might be related to
the surface charges present on each entity present: oligonucleotides are negatively
charged and TNF-α possesses a positively charged heparin-binding domain. Thus,
the electrostatic attraction caused these non-covalent interactions.
Figure 3.38: Band-shift assay resulting from the incubation of 50µm TNF-α with
1 µm DNA: Cy5-ssDNA (1 and 2), Cy5-half-dsDNA (3 and 4), and Cy5-y-shape DNA
(yDNA) (5 and 6). Lanes 1, 3 and 5 are the no protein control. Lane number 7 is
TNF-α only control. 4% agarose gel.
Affinity Titration From several gel runs, we were able to estimate the Kd of TNF-α
binding to Cy5-ssDNA, Cy5-half-dsDNA and Cy5-yDNA as below as 5µm, 2 µm, and
1 µm, respectively (Figure 3.39). The titration of Xsmall was also performed (Figure
3.40). A Xsmall’s structure Kd could be estimated to be around 1 µm.
It must be noticed that the nature of interaction between different DNA structures
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and TNF-α changes. When using ssDNA or dsDNA the binding to TNF-α seemed
to cause oligomerisation by cross-linking. This happened in such degree that a signi-
ficant amount of the bound complex was not even able to move away from the wells.
However, when using the yDNA or Xsmall, even though there was a strong binding
to TNF-α, this effect did not appear because they could migrate from wells.
Bio-Layer Interferometry
In an attempt to determine more exactly the binding affinity of TNF-α to DNA and
heparin, we developed a method on a BLI platform. In this section, we explore the
protocol development and optimisation.
Anti-Penta-His Sensors Test The first approach was to use anti-penta-His sensors,
which captured the His-tagged TNF-α. The binding to the sensors was clear and
reproducible among different experiments, see Figure 3.41a. However, when bind-
ing experiments with DNA were performed, the signal dropped after each cycle of
regeneration. Due to the signal drop, it became difficult to calculate a definite Kd.
Only an estimate was possible to retrieve, which was around p44.7˘ 4.7q µm (Figure
3.42).
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(a)
(b)
(c)
Figure 3.39: Band-shift assay resulting from the incubation of 100 nm Cy5-ssDNA
(a), Cy5-half-dsDNA (b), and Cy5-yDNA (c) with increasing TNF-α concentrations,
as indicated on the image. 4% agarose gel.
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Figure 3.40: Incubation of 1µm Xsmall with increasing TNF-α concentrations, as
indicated on the image. 20 bp ladder, 4% agarose EtBr gel.
(a) (b)
Figure 3.41: Regeneration and loading of three anti-penta-His sensors with 588 nm
TNF-α after one (a) and two (b) consecutive loads.
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(a) (b)
Figure 3.42: Binding cycles with three anti-penta-His sensors (a) and binding
kinetics for the three highest concentrations of S-DNA (b). Sensor 1 was incubated
only with increasing concentrations of S-DNA, from 1.23 to 100µm. Sensor 2 was
incubated with S-DNA, like sensor 1, plus 588 nm TNF-α. Sensor 3 was incubated
only with 588 nm TNF-α.
Inhibition of TNF-α Binding to Amine Reactive Second Generation Sensors We then
tested ARG sensors, which have a negatively charged surface (free carboxylic groups)
to which TNF-α bound directly to. To explore in more detail the consequences of
sensor charges, we also tested APS sensors. These sensors display amino groups
on the surface, which become positively charged after protonation. APS and ARG
sensors were loaded with TNF-α. The ARG sensor yield a very strong binding with
a clear dissociation step and, as expected, the APS sensor did not show any binding
(Figure 3.43). Thus, TNF-α interacted with ARG and was repulsed by APS.
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Figure 3.43: Loading of APS and ARG sensors with 1.44 µm TNF-α.
In a first trial of DNA and TNF-α binding measurement, we co-incubated 144 nm
TNF-α with S-DNA from 0.1 to 100µm. The obtained binding values were inter-
esting, suggesting a decrease of TNF-α binding to the sensor correlated with the
increase of DNA in the system, as seen on Figure 3.44a. However, the control sensor
with no DNA had its signal decreased consistently throughout the cycles of load-
ing/regeneration. To normalise the binding values, we calculated a ratio for each
condition between the control and test sensors (Figure 3.44b). It was again ob-
served that increasing concentrations of DNA yielded lower TNF-α binding to the
unmodified sensors.
98
(a) (b)
Figure 3.44: Co-incubation of 144 nm TNF-α with increasing concentrations of
S-DNA. S-DNA at 100 nm corresponds to the first regeneration cycle, 1 µm to the
second, 10µm to the third, and 100 µm to the fourth. Total binding values (a) and
binding ratios at 599 s (b).
The regeneration cycle was the next step to be improved and several conditions
were tested. First, we tried a low pH buffer with a high concentration in salt plus
glycine. The resulting binding and loss of signal were not optimal, see Figure 3.45,
as the control sensor lost sensitivity very fast and at the last cycle had a third of its
initial value. Then, we tested a regeneration buffer with high pH, 150 mm NaOH.
With NaOH, the control sensor did not lose signal and the test sensor generated
reliable data that was in accordance to the data obtained before (Figure 3.46a).
When the binding ratio was plotted, the binding/no binding trend was obvious and,
once again, the presence of DNA reduced TNF-α’s binding to the ARG sensor (Figure
3.46b).
99
(a) (b)
Figure 3.45: Co-incubation of 5µm TNF-α with increasing concentrations of S-
DNA, using as regeneration buffer 10 mm glycine with 2m NaCl, pH 1.5. No S-DNA
corresponds to the first regeneration cycle, 1µm to the second, 5 µm to the third,
25 µm to the fourth, and 125µm to the fifth. Total binding values (a) and binding
ratios at 599 s (b).
(a) (b)
Figure 3.46: Co-incubation of 5µm TNF-α with increasing concentrations of S-
DNA, using as regeneration buffer 150 mm NaOH. No S-DNA corresponds to the
first regeneration cycle, 1µm to the second, 5 µm to the third, 25 µm to the fourth,
and 125 µm to the fifth. Total binding values (a) and binding ratios at 599 s (b).
Binding Ratios Determination We put aside the goal of calculating a definite Kd and
aimed at comparing binding ratios between different constructs and materials. First,
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we co-incubated 5µm TNF-α with 5 µm of several DNA structures: ssDNA, half-
dsDNA, yDNA and S-DNA. The binding of TNF-α to the sensor at 599 s was, at
least, halved in all conditions, see Figure 3.47. The structure providing the lowest
binding ratio was yDNA. When the experiment was repeated at a lower concentra-
tion of both DNA and TNF-α (1µm) the decreased binding pattern for all structures
was still visible, but it was not as strong (Figure 3.48). Then, we tested the same
DNA structures coupled to the small molecule 2a (TNF-α inhibitor), using S-DNA as
binding standard. TNF-α binding was reduced in a smaller extent when co-incubated
with DNA-2a than it was when it was co-incubated with the same unmodified struc-
tures (Figure 3.49). Still, the binding with yDNA-2a was less than S-DNA.
(a) (b)
Figure 3.47: Co-incubation of 5µm TNF-α with 5µm of several DNA structures.
Total binding values (a) and binding ratios at 599 s (b).
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(a) (b)
Figure 3.48: Co-incubation of 1µm TNF-α with 1µm of several DNA structures.
Total binding values (a) and binding ratios at 599 s (b).
(a) (b)
Figure 3.49: Co-incubation of 1µm TNF-α with 1 µm of several DNA structures
coupled to 2a and S-DNA. Total binding values (a) and binding ratios at 599 s (b).
Testing heparin and its derivatives, it was visible a very strong decrease of binding
to the sensor, even stronger than with DNA: more than half less in the 5 µm TNF-α
versus 5µm heparin condition, see Figure 3.50. Even when the concentration was
lowered to 1 µm, the binding reduction was more prominent than the one of DNA for
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the same concentrations, see Figure 3.51. The unmodified heparin had the strongest
effect on the binding of TNF-α to the ARG sensor.
(a) (b)
Figure 3.50: Co-incubation of 5 µm TNF-α with 5 µm of heparin and its derivatives.
Total binding values (a) and binding ratios at 599 s (b).
(a) (b)
Figure 3.51: Co-incubation of 1 µm TNF-α with 1 µm of heparin and its derivatives.
Total binding values (a) and binding ratios at 599 s (b).
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Microscale Thermophoresis (MST)
The third method we applied to unveil the affinity of TNF-α to DNA was MST. The
results were in accordance with the values we obtained using the band-shift assays.
As it can be seen on Figure 3.52, the determined Kd of TNF-α to Cy5-full-dsDNA
was p10.7˘ 2.0q µm and to Cy5-yDNA was p4.9˘ 1.1q µm. At higher concentrations,
TNF-α oligomerised.
Figure 3.52: Dose-response-fit of DNA with TNF-α. The concentration of Cy5-full-
dsDNA and Cy5-yDNA was 10 nm and TNF-α concentration ranged from 122.5 nm
to 250 µm.
3.2.2 Cell Toxicity Assays
TNF-α’s cytotoxic effect on L929 cells (Mus musculus fibroblasts) is the most ex-
plored in vitro model for this cytokine [210], causing either apoptosis or necrosis
[211]. For TNF-α activation there must be co-incubation with ACT-D (transcrip-
tion inhibitor) or CHX (translation inhibitor).
The cells were first sensitised to TNF-α with 2 µg mL´1 ACT-D or 8 µm CHX, see
Figure 3.53a. After observing a similar toxic profile for both molecules, we proceeded
to co-incubate them with 5µm DNA or heparin for 24 h (Figure 3.53b). As reported
by Stull et al. [210], ACT-D intercalated DNA, leading to optimal cell viability. As
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for heparin, the effect was gone. Thus, CHX was chosen for the following experi-
ments using DNA.
For the cell viability graphs presented in this section, the 100% cell viability corres-
ponds to control wells, where cells were incubated only with their growth medium
and 8µm CHX. Both commercial and expressed in house TNF-α were tested in the
presence or absence of DNA and generated equivalent results.
(a) (b)
Figure 3.53: TNF-α co-incubated with 8 µm CHX or 2 µg mL´1 ACT-D (a) and
DNA or heparin (b).
Oligonucleotides Co-Incubation
When short DNA sequences that were single, partially or totally annealed were
co-incubated with 0.01 to 1 ng mL´1 TNF-α, there was an increase up to 20% of
cytotoxicity (Figure 3.54). At 10 ng mL´1 TNF-α, cell viability was similar in every
condition.
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(a) (b)
Figure 3.54: Each DNA construct was in a final concentration of 5 µm, in the
presence of 8 µm CHX. In (a), there is the effect of ssDNA, full-dsDNA, yDNA, and
S-DNA. In (b), there is the effect of shortDNA, half-dsDNA, Xsmall and a double-
stranded aptamer library (dsAPT).
To explore the time link between oligonucleotides and TNF-α enhanced cytotox-
icity, some cells were pre-treated with DNA in the absence of TNF-α, see Figure
3.55. DNA pre-incubation for 2 h, followed by DNA removal was not able to in-
duce significant increase of cell death when TNF-α was later added to the system.
In parallel, DNA pre-incubation for 2 h, removal plus a new incubation for 24 h of
DNA with TNF-α was able to generate enhanced cytotoxicity levels, similar to the
previous observations.
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Figure 3.55: In the DNA condition, the incubation of TNF-α with DNA was carried
for 24 h. The DNA pre-treatment condition consisted of incubating the cells, without
TNF-α, with DNA for 2 h, removing it after. In the condition DNA pre-treatment
plus DNA, DNA was added to the pre-treated cells with TNF-α for another 24 h.
Each DNA construct was in a final concentration of 5 µm, in the presence of 8 µm
CHX.
There are several reports describing enhanced cytotoxicity of DNA sequences
carrying CpG motifs, which can act as immunostimulants [21]. To avoid this, we
designed sequences that did not potentially present CpG motifs. As seen on Figure
3.56, the cytotoxicity was not too different from the initial sequences that could
harbour CpG motifs. Meaning that either the effect was not present in any condition
or, if present, was not influencing the system significantly.
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Figure 3.56: Cell viability assay co-incubating TNF-α with 5µm of several DNA
structures that did not harbour CpG motifs, in the presence of 8 µm CHX.
Co-Incubation with Known Cytotoxics To explore whether DNA has a synergic effect
with other cytotoxics, or whether the synergic effect is specific with TNF-α through
physical interaction, we tested other cytotoxics in addition to CHX and ACT-D. The
cells were incubated with 5µm taxol and 5 µm irinotecan. It was clear that TNF-α
bioactivity was independent from these two cytotoxic agents and dependent on the
DNA constructs only (Figure 3.57). There was a strong cell viability decrease every
time DNA was added to the cytotoxic plus TNF-α system, regardless of the initial
cytotoxic effect caused by taxol or irinotecan.
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(a) (b)
(c)
Figure 3.57: Co-incubation of 0.1 ng mL´1 TNF-α with 5 µm DNA and 5 µm taxol
or irinotecan, in the presence of 8 µm CHX. The control experiment had no cytotoxic
(a). In (b), taxol was added and in (c), irinotecan.
RNA Co-Incubation We also investigated the influence of RNA in this system. Com-
paring with S-DNA, RNA generated a lower cytotoxic effect, see Figure 3.58.
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Figure 3.58: Cytotoxicity resulting from 5µm RNA co-incubation with TNF-α, in
the presence of 8µm CHX.
Heparin and Derivatives Co-Incubation
Furthermore, we tested another negatively charged biopolymer effect in this system:
heparin and heparin coupled to TNF-α inhibitors, 2a and 2c [112]. As tested previ-
ously on BLI, we knew that heparin and TNF-α also had a significant binding. All
heparin conditions showed slightly enhanced cytotoxicity too (Figure 3.59a). Inter-
estingly, heparin-2a and -2c had quite a strong impact on cell viability, even reversing
the expected inhibition caused by the small molecules coupled to it.
As tested for the DNA constructs, we investigated the effect of the heparins on cell
viability while co-incubating them with taxol and irinotecan (Figure 3.59b). 5µm
taxol or irinotecan with the heparins yielded a 20 to 30% lower cell viability, but when
co-incubated with TNF-α, the value went lower, at least, 10%. This corroborates
our hypothesis that DNA and TNF-α interaction was essential for cell death.
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(a) (b)
Figure 3.59: Heparin and its derivatives (5 µm) cytotoxic effect when incubated
with increasing TNF-α concentrations (a). Co-incubation of 5 µm taxol or irinotecan
with 5 µm heparin-2c, with or without 0.1 ng mL´1 TNF-α (b). All conditions are in
the presence of 8µm CHX.
TNF-α Modifications Effect on Cytotoxicity
TNF-α-NVOC During this study, we modified TNF-α with fluorescein and Cy5.
When these modifications were performed, the affinity to DNA seemed to be dimin-
ished or even totally destroyed. As we realised this interaction could be manipulated,
we modified TNF-α with a NVOC group to create a light-switch that could be used
to change its interaction with DNA. Using a ratio of 5 eq. of NVOC per TNF-α
monomer, we generated a TNF-α that resembled the unmodified version, with or
without UV exposure (Figure 3.60). The caged TNF-α co-incubated with DNA had
a lower cell death enhancing effect, when compared with the controls of unmodified
TNF-α. Adding DNA, the cell viability decreased more significantly in the uncaged
version of TNF-α.
When TNF-α was modified in a ratio of 25 eq. per monomer, the controls with no
DNA were again similar to no UV exposure, as well as the conditions with DNA. The
caging/uncaging association with DNA effect seemed to be gone, see Figure 3.61.
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(a) (b)
Figure 3.60: Influence on cell viability of TNF-α-NVOC with (a) and without UV
exposure (b) with 5µm S-DNA, in the presence of 8 µm CHX. TNF-α-NVOC is in a
five times excess over each TNF-α monomer.
(a) (b)
Figure 3.61: Influence on cell viability of TNF-α-NVOC with (a) and without UV
exposure (b) with 5µm S-DNA, in the presence of 8 µm CHX. TNF-α-NVOC is in a
25 times excess over each TNF-α monomer.
3.2.3 Circular Dichroism Spectra of TNF-α Structure
Using CD, we monitored TNF-α’s structural shifts following α-helix markers, which
are characterised by decreased ellipticity at 208 and 222 nm. Also, the β-sheet
marker, which shows as a decrease at 217 nm, was tracked. As reference and con-
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trols for this section of experiments, we provide the stability data for TNF-α (Figure
3.62a) and the standard DNA spectra of the constructs used (Figure 3.62b).
(a) (b)
Figure 3.62: 10 µm TNF-α stability for 60 min (a). 10 µm DNA standard spectra
(b).
On Figure 3.63a, we see that the native TNF-α conformation shifted to lower el-
lipticity values in the 200 to 240 nm range, when co-incubated with hybridised DNA,
two fully-complementary strands (full-dsDNA), or yDNA. When the α-helix markers
were plotted (Figure 3.63b), the values for 208 and 222 nm were more negative than
the control when TNF-α was incubated with DNA, suggesting a larger presence of
α-helix in the trimer. Also the typical β-sheet marker was decreased in comparison
to the TNF-α control.
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(a) (b)
Figure 3.63: 10 µm DNA incubated with 10 µm TNF-α for 60 min (a). 208 and
222 nm are α-helix markers, and 217 nm is a β-sheet marker (b).
Altogether, these values suggest that the TNF-α native structure was indeed
altered by DNA presence. Specifically, the increase in α-helix content might have
been related to the increased TNF-α-induced cell death. More DNA structures
(ssDNA, half-dsDNA, and S-DNA) were also tested and there were always significant
shifts in TNF-α’s conformation. Both α-helix and β-sheet markers were altered
(Figure 3.64).
114
(a) (b)
(c)
Figure 3.64: 10µm DNA spectra (a). 10 µm DNA incubated with 10µm TNF-α
for 5 min (b). 208 and 222 nm are α-helix markers, and 217 nm is a β-sheet marker
(c).
3.2.4 TNF-α Monomers Dynamic Study
The hypothesis was that TNF-α monomers dynamic is affected by the presence of
charged biopolymers, such as DNA and heparin. For that end, we explored many
possible methodologies, but ended always with inconclusive results.
The presented homoquenching experiment, albeit unsatisfactory, gave us some in-
teresting preliminary results. The experiment was based on the concept of relief of
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fluorescence homoquenching [200], meaning that the fluorescent moieties of the same
kind are close enough in space that they quench themselves. For this experiment,
we labelled TNF-α with Cy5, proceeded to mix unlabelled with labelled entities
and co-incubated them with S-DNA (Figure 3.65a). It can be seen that 2µm un-
labelled TNF-α yielded no fluorescence signal. When 10 nm TNF-α-Cy5 was added
to the unlabelled TNF-α, the fluorescence signal was higher than TNF-α-Cy5 alone,
suggesting that the dynamic exchange of monomers lead to reduced self-quenching.
Adding S-DNA to the system, in the presence of only labelled TNF-α, generated al-
most the same signal in both conditions. When TNF-α unlabelled was added, there
was an increase of fluorescence, because the fluorescent signal was released. Normal-
ising the results by the fluorescence obtained for 10 nm TNF-α-Cy5, when DNA was
present, the fluorescence was less than in its absence (Figure 3.65b). Throughout
120 min, the release of fluorescence was less when DNA was present, suggesting that
the system was not as dynamic as in its absence.
(a) (b)
Figure 3.65: Incubation result of 2 µm TNF-α with 10 nm TNF-α-Cy5 and 5µm
S-DNA during 120 min (a). Fluorescence normalisation with 10 nm TNF-α-Cy5 (b).
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4
Discussion
4.1 DNA-Based Diversity Modelling and Analysis
This project proposes a synthetic DNA library as an ideal medium for establishing
experimental systems to model large populations of high complexity and dynamics.
For example, a randomised 20-base sequence (N20) contains more than one trillion
different DNA sequences (420). Where only 10 µL of 10 nm N20 solution has the
size of the human population and, statistically, each molecule represents a unique
individual.
To explore this effect, we assigned a fully complimentary duplex with a F of 1.0.
Mismatching leads to lower F values, e.g., A ´ X10 ´ B/A
1 ´ X 110 ´ B
1 (medium
diversity) and A´X20´B/A
1´X 120´B
1 (high diversity) duplexes have F values of
0.5 and 0.1, respectively (X and X 1 indicate mismatching in the randomised region),
see Figure 3.9. Astonishingly, throughout the PCR cycles, although the production
of full length DNA was not affected by using either A´S1´B or various libraries as
templates, the time courses of F values differed from each other dramatically (Figure
3.2).
We postulate that in the initial phase, primer concentrations are much higher than
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those of full length DNA and probabilistically self-assembled A ´ X ´ B/B1 and
A1 ´ X 1 ´ B1/A are more abundant than A ´ X ´ B/A1 ´ X 1 ´ B1 (Figure 4.1a).
A´X ´B/B1 and A1´X 1´B1/A produce A´X ´B/A1´X 1´B1 in the presence
of DNA polymerase (X/X 1 means the fully complimentary pair synthesised by DNA
polymerase, according to the template). The newly synthesised fully complimentary
A´X´B/A1´X 1´B1 has an F value of 1.0. In later phases, primers are consumed
and full length DNAs are abundant. Hence, A ´ X ´ B/B1 and A1 ´ X 1 ´ B1/A
are much less prevalent than A´X ´ B/A1 ´X 1 ´ B1 (Figure 4.1b). The duplexes
generated by annealing form mismatching pairs with lower F values, in contrast to
the duplexes produced by polymerase, where F = 1.0. There is a turning point in the
course of a high diversity library, as the increase of F caused by newly synthesised
fully complementary duplexes equals the decrease of F caused by the re-annealing
of DNA. This generates mismatched pairs through re-shuffling among the library
members (Figure 3.8).
To relate F to an experimentally measurable parameter, we explored the quick an-
nealing effect of mismatched templates that are less stable at 72 ˝C, leading to weaker
dye binding and lower fluorescence (Figure 3.10). Experimentally, we demonstrated
that mismatches between strands had a direct negative effect on fluorescence sig-
nal and melting temperature. It was observed that the mismatched templates were
somehow paired, e.g., two and four mismatches, along the decreased melting tem-
perature values. This similar effect for different mismatched samples reflected the
fluorescence signal decrease obtained during the screening of diverse libraries. The
largest difference observed in the fluorescence signal monitoring occurred between
X8 and X10. As for the melting curves, there was not that sharp difference, but
there was a clear cut between types of samples. These types of samples seemed to
be comprised of similarly mismatched templates. As an explanation for these res-
ults grouping, we believe could be the physical interaction per se of SYBR Green
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(a)
(b)
Figure 4.1: PCR amplification scheme when there is one (a) or many (b) templates.
The green star depicts the intercalated fluorescent dye.
I to dsDNA. As referred to in the introduction, SYBR Green I intercalates dsDNA
in portions of 3.5 bases and in its minor groove. The specificity of this interaction
might be the explanation for such results.
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We amplified libraries of different diversities in optimised conditions, see Figures 3.3
and 3.4 with libraries and primers concentration titration, respectively. In parallel,
a simulation of the same conditions was done (Figure 3.18). The lower the diversity,
the closer the amplification curve would be to the one template curve. Increasing
diversity led to the transformation of a sigmoidal (lowest diversity) to a bell shape
curve (highest diversity). This effect was consist among concentrations.
We continued our study with the study of the randomised sequences’ nature. To
start, and emulating DNA strands carrying codes in a DECL setting, we created
templates that had the same total number of randomised nucleotides, 20, but dis-
tributed in different segments. For a given library Xn, when n is larger than 16,
each sequence in 10 µL at 1 nm is statistically unique. However, each sequence in
X2{10 and X4{5 is represented a few thousand times, see Figure 3.11. Even though
the degeneration was very different, the amplification had similar profiles.
To understand in more detail the impact of diversity in the amplification, we designed
ten different templates (Sx) with a central segment of 20 nucleotides in which, at
least, 15 nucleotides were different among each other. This design was opposed to
the original one (X20), which had a central segment with 20 randomised positions.
This randomisation could mean zero to 20 different nucleotides. This new library
had a higher intrinsic diversity than X20. The amplification curve for a mix of the ten
highly-diverse templates should have a profile similar to X20, if the dynamic duplexes
reshuffling did not occur during the annealing step in each cycle. However, the curve
obtained showed that thermodynamic re-equilibration played a part, even though it
was too inefficient to create perfect matching between all sequences (Figure 3.13).
Decreasing the sub-library number gradually generated a standard RT-PCR curve.
Another way we studied the oligonucleotide population was by manipulating its
growth, considering primers essential resources. Primers are inter-dependent and
limiting one damages the population exponential growth, as described in AsyPCR.
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Applying classical AsyPCR, one primer is in a much lower concentration, reducing
the entire molarity of the system (Figure 3.15). The kinetics are governed by the use
of one primer, preventing the comparison of libraries of different diversity. Modifying
this method, we performed AsyPCR with primers shorter than the standard 20 bp
(A12, A15, A18), with lower annealing temperatures (Figure 3.17). Polymerisation
with these primers, plus B1, becomes the rate-limiting step. A18 was the only primer
able to produce similar amplification to A, while A15 showed a strong delay and A12
had no amplification at all. When a highly diverse library was used as template, the
simulation experiment predicted that the turning point would be later and appear at
a lower F value. The synthesis of fully complementary duplex became slower, so the
resulting increase of fluorescence was exceeded by the counter effect associated with
DNA reshuffling at lower full length DNA concentration. In particular, A15B
1 illus-
trates the library diversity and the effect caused by primer imbalance and enabled
the generation of kinetic-controlled DNA synthesis. This design could be used to
model conditions in which the inefficient supply of one resource will become decisive
for a population’s progress, as in an adaptation scenario.
Based on the AS-PCR method, we elongated the primers to bias population growth.
A20`1, A20`5 andA20`10 selectively amplified 1/4, 1/4
5 and 1/410, respectively, ofX20,
reducing diversity (Figures 3.20 and 3.21). The amplified products have decreased
diversity. This setup enables the discrimination by nucleotide. Only templates able
to pair with the extra nucleotides presented by the primers are able to carry ampli-
fication. So, it is possible to pinpoint a defined sequence.
To further prove our method as a possibility to model heterogeneous populations
under dynamic progress and systems that can be pressured by other selective forces,
libraries with restriction sites were designed, XEcoRV and XSmaI , see Figure 3.25. As
the full complementary duplexes are the substrate of the used endonucleases (Fig-
ure 4.2a), these segments could be used as a selection mechanism during population
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growth. The crescent heterogeneity of the system caused by DNA reshuffling yield
population protection against endonuclease digestion, due to the elevated number of
mismatches (Figure 4.2b).
During this experiment, we observed for the first time the reocurrence of fluores-
cence after an extended number of amplification cycles, see Figure 4.2c. Analysing
these RT-PCR products of high fluorescence signal by urea-PAGE (Figures 3.30 and
3.31) and AFM (Figures 3.33 and 3.34), we visualised large and complex 3D DNA
structures. On the basis of this assembling, we hypothesise that a mixture of a large
amount of random templates could have a staggering number of potential interac-
tions. This leads to structures with partial complementarities involving more than
two strands. With a library as diverse as X20, the number of interactions possible
surpasses the power of computation. Therefore, we suppose that a highly diverse
library under polymerase action could evolve complex structures, more than a non-
diverse library. Contrastingly, such structures have not been observed with genomic
DNA samples [212].
To establish our method’s relevance as also a tool and not only a modelling sys-
tem, we designed an experiment where our method could be used as a complement of
DECL. A mock-library with SA-resin plus biotin- (strong) or iminobiotin-modified
(weak) oligonucleotides were used as models: LibA represented a library with few po-
tent binders without weak binders; LibB simulated a library with few weak binders;
LibC had many weak binders; and LibD represented a library with few high affinity
ligand and many weak binders (Figure 3.36). Mimicking stringency by varying the
number of washes, it was possible to evaluate the population behaviour towards such
conditions. After one washing step, all weak and strong binders were present in the
respective populations. After two washing steps, the strong binders became the main
population in LibA and LibD. In LibB, only one type of weak binder was present
and this continued to be the major binder due to lack of competition. LibC profile
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(a) (b)
(c)
Figure 4.2: Amplification curve when there is one template and there is protec-
tion against restriction enzymes (a). When there are many templates, there is no
protection due to mismatch (b). Reoccurrence of fluorescence for prolonged PCR
amplification (c). The green star depicts the intercalated fluorescent dye and the
scissors represent the restriction enzymes.
did also not change, because the whole population was composed of weak binders
and, once again, no strong competition was present. Using this method, it is possible
to estimate the amount of DNA conjugates captured by the protein. Furthermore,
it can also distinguish different types of populations, according to their binding po-
tency, which is even more relevant for DECL. Piggy-back ridding on the existing
DECL setups, where libraries contain millions of different compounds with respect-
ive codes generated through combining sub-codes that contain tens to hundreds of
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members flanked by two constant strands, we can analyse diversity of each sub-code
region.
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4.2 Physical Environment Regulation of TNF-α Activity
The exact mechanism by which TNF-α rules its dynamics is still blurred. It is known
that this cytokine must be in a trimer conformation to exert activity. Monomers and
dimers are widely assumed to be inactive, see Figure 4.3. The triggering of inflam-
mation cascades probably plays an important role in how TNF-α finally assembles
into an active trimer in vivo.
Figure 4.3: Proposed mechanism for TNF-α’s dynamic structure. At low concen-
trations, it exists as a monomer (1). As the concentration increases, it assembles
into a dimer (2) or even a trimer (3). All the conformations are not covalently linked
and are subject to temporal variations of concentration.
The binding, bioactivity, and structural results we got of DNA’s interaction with
TNF-α are strong pieces of evidence supporting the idea that this direct relationship
exists. We hypothesise that DNA could alter TNF-α structure and, consequentially,
its activity. These interactions are thought to be linked to electrostatic interactions
between the positively charged TNF-α and the negatively charged oligonucleotide.
So, theoretically, this effect could be observed for any other negatively charged bi-
opolymer, such as heparin. Some preliminary data points in this direction.
For a better understanding of TNF-α’s direct interaction with DNA (Cy5-modified
or wild type), a set of band-shift assays was performed. At high concentrations of
TNF-α (50µm), DNA’s migration was shifted or generated smears, see Figure 3.38.
Interestingly, there was often a residue amount of DNA blocked inside the wells,
which seems to be caused by the non-covalent cross-linking between the trimer and
DNA. The same was not observed for the yDNA and Xsmall constructs (Figures
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3.39 and 3.40), suggesting its binding to TNF-α is established in a different man-
ner. Titration experiments were performed and the estimated Kd of TNF-α to DNA
was in the micro-molar range. Using another method, MST, values obtained for the
binding affinity of yDNA were also in the low micro-molar range (Figure 3.52).
We proceeded to study the interaction of TNF-α with DNA in more detail. Us-
ing BLI, we tested TNF-α’s interaction with a negatively charged environment. To
start, we saw that TNF-α had strong binding to the carboxyl-modified surface (ARG
sensor) and no binding to the amino-modified one (APS sensor), see Figure 3.43.
After, we observed that co-incubation with 1 µm DNA was able to inhibit in large
extent the binding of TNF-α to the negatively charged surface (Figure 3.48). The
results were even more pronounced using 5 µm DNA, up to around 50% (Figure 3.47).
Similar results were obtained using highly sulfated oligosaccharides, such as heparin
(Figures 3.50 and 3.51).
The co-incubation with negatively charged biopolymers, such as DNA, RNA or hep-
arin, increased TNF-α’s cytotoxicity. For all DNA shapes tested, there was a consist-
ent increase of about 20% cell death in every condition, see Figure 3.54. The same
profile was obtained while using heparin and its derivatives, see Figure 3.59a. This
synergy was not dependent on CpG motifs immunostimulation (Figure 3.56) or other
cytotoxics lethality (Figure 3.57). We also prepared a light-switchable TNF-α, where
light had little effect of TNF-α itself, but made the whole system more sensitive to
DNA-mediated up-regulation of TNF-α activity (Figures 3.60 and 3.61).
We studied too how TNF-α’s conformation is changed throughout these interactions
by CD spectroscopy, see Figures 3.63 and 3.64. Different forms of DNA seemed to
generate conformational changes, such as dsDNA and yDNA reducing the ellipticity
at 217 nm strongly, an α-helix marker. TNF-α has a very weak signal at 250 nm,
so the changes at this point can be assigned to the structural changes in DNA.
Also, DNA shows a very weak signal at 217 nm. Thus, spectra interferences can
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be excluded. There are many reports about how high temperatures and low pH can
generate α-helix in TNF-α and how it is linked to higher cytotoxicity [191]. Thus, we
believe the enhanced bioactivity when co-incubating with DNA could also be due to
the appearance of α-helix. DNA interferes with the correct disposition and structure
of TNF-α, inducing significant changes in its bioactivity.
Our final goal was to understand in detail the dynamics of TNF-α monomer as-
sembly and how this could be influenced by the physical environment. We tried a
large range of methods, e.g., homoquenching, enzyme-linked immunosorbent assay
(ELISA), or Fluorescence Correlation Spectroscopy (FCS). However, none gave us a
clear result explaining this effect. The main drawback was the detection limit, even
for ELISA. We had to work in a range of low pico-molar concentrations, guarantee-
ing that all TNF-α present in solution was in a monomer conformation and not in
a dimer or a trimer. In most attempts, only higher concentrations of TNF-α were
detectable or the effect was so small that we could not register it. So, our intention of
demonstrating how DNA interferes with these assemblies was not possible to fulfil.
Nevertheless, the results from the homoquenching experiment gave us some hints
about the system in accordance to our initial hypothesis (Figure 3.65). The results
show a difference in the whole system dynamics with or without DNA, suggesting it
is able to lock the free movement of TNF-α monomers. More experiments must be
done.
As discussed in the introduction, the average cfDNA in blood is in the low micro-
molar range [213] and it can be detected in several pathologies, from cancer to
auto-immune diseases. For TNF-α, concentrations can range from low pico-molar
to high nano-molar, according to the physiological situation, e.g., higher in inflam-
mation [171]. The known binding affinity of anti-TNF-α Abs, current therapies, is
around pico-molar and the affinity values we propose of DNA to TNF-α are in the
micro-molar range. Thus, this would fit quite well the scenario in which cfDNA
127
would be called to interact with TNF-α, when this is elevated, see Figure 4.4. DNA
would be able to bind to TNF-α, change its structure and activate it for a stronger
biological response.
Figure 4.4: Comparison of biological levels in vivo and affinity to TNF-α by DNA
and Abs. The specificity of Ab detection and binding is based on its ability to
recognise TNF-α in very low concentrations (pico-molar). DNA’s interaction with
TNF-α is unspecific and only possible when both concentrations are closer in a micro-
molar range. This rough regulation prevents the activation of TNF-α by DNA when
concentrations in vivo do not cross the reactivity threshold.
As many different biomolecules are present in blood in a wide range of concen-
trations, their local concentrations can be changed and reflect whichever stimulus
or signalling at a given time. These changes can result from genetic expression or
interactions with other bioactive molecules. This unspecific and low-potency regu-
lation of DNA on TNF-α can happen in vivo: if the abundant biomolecule X (e.g.,
DNA or heparin) interacts and regulates the signalling molecule Y (e.g., TNF-α), the
concentration fluctuation of X must be in the same range of the Kd between X and
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Y . In other words, Y ’s activity must be regulated in a subtle way in a physiological
context; X is abundant and interacts with Y altering its activity. X biofunction can
be influenced by its own concentration (CY ) and X’s concentration (CX). If CX is
constantly much higher than the dissociation constant between X and Y (KdXY ),
under physiopathological conditions, X becomes a pseudo-intrinsic feature of the
biological activity of Y . If CX is constantly much lower than KdXY , it will have no
effect on Y ’s activity. So, if CX is in the range of KdXY , a change in CX can lead to
a modification in the biological activity of Y . Other regulation mechanisms, such as
post-translational modifications, can also be involved.
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5
Conclusion
This dissertation explores DNA oligomers in two distinct functions: as a data mod-
elling system and as a participant in physical interactions with other biomolecules.
On both functions, DNA’s abilities are explored beyond the classic storage and reg-
ulation of genetic information.
As a coding unit, we illustrate the relationship between code-diversity and dynamics
of self-assembly. The DDMA method described is based on a very simple principle
and its experimental measure is accurate and robust, which is corroborated by math-
ematical simulations. Exploring the design of different libraries and using primers
with various kinetics and selectivity, we demonstrated that we could analyse, manip-
ulate and evolve a pool of DNA strands. The DDMA method is able to:
• evaluate quantity, quality and diversity of a DNA library,
• tune kinetics of primers’ binding to a template, biasing growth and modelling
specific situations,
• control primers’ selectivity for a template, reducing a diverse population,
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• incorporate restriction sites, creating an experimental model in which hetero-
geneity has protective effect,
• and form large DNA structures when the system is subjected to extensive PCR
cycles.
Our diverse DNA libraries behave as synthetic societies and can be used to model het-
erogeneous populations. They can simulate different types of diversity and function.
The dynamic interactions among the individual members govern the time course and
final product of a PCR reaction. These can be used to build models to verify hypo-
theses and lead to new discoveries. As postulated by [37], DNA could be the solution
to one of the limitations existing in population modelling and be the simplest setup
able to simulate an observation.
The unexpected formation of complex 3D DNA structures in extended PCR cycles
showed a material fundamentally different from low-entropy structures generated by
methods such as DNA origami. Clearly aware that DNA amplification under PCR
conditions does not occur in cells, a related DNA amplification process in a pool of
diverse sequences and the production of high-entropy structures can take place in
physiological conditions, e.g., DNA autoimmune disease. DNA-associated autoim-
munity has been found in many pathological conditions, but its mechanism remains
unknown.
Furthermore, the RT-PCR method also has application in biochemical analysis, e.g.,
to analyse the mixture of oligonucleotides from selection experiments (SELEX or
DECL). Plus, the use of DNA libraries as synthetic societies can open new venues
to model complex and diverse populations.
In the concrete case of DECL, some of its major struggles is to unravel a few strong
binders from large combinatorial chemical libraries, being able to reduce the impact
of unspecific or weak interactions between DNA-conjugates and target proteins. Only
131
after sequencing and data analysis, it is possible to identify the hit compounds and
this is a bottleneck. DDMA can evaluate almost instantly the library diversity during
the selection process. Our method improves information regarding how much DNA
conjugates were captured by protein and how strong their affinity might be. Since
DECLs can have millions of different compounds, the codes are generated through
combining sub-codes. Each sub-code region typically has tens to hundreds of mem-
bers flanked by two constant strands. So, assuring there is a primer region, by its
manipulation, the diversity of each sub-code region can be easily analysed through
DDMA.
Our method represents a different approach to use DNA as variable and information
storage [160]. As compared to more complex designs of DNA computing with up to
hundreds of unique strands [159], our libraries can harbour more than one trillion
different sequences and, in principle, has no size limit. Though, it is not aimed at per-
forming classic operations, DDMA can be used to model systems beyond the power
of computation. It is possible to simulate the collective behaviour of a heterogeneous
and dynamic population and its underlining probabilistic structure associated with
an astounding number of random interactions.
The ability of DNA to participate as an active unit in the regulation of a target
protein, TNF-α, altering its physical environment also caught our attention. We
explored the interaction between DNA, also heparin, and TNF-α. This binding
was consistently estimated to be around the low micro-molar range and structural
conformation studies confirmed changes in TNF-α structure. All these results were
translated into a regulation of biological function, when we observed that TNF-
α’s inherent cytotoxicity was further boosted by the presence of negatively charged
polymers. The proposed explanation for this binding is the existence of unspecific
interactions between the positively charged TNF-α and the negatively charged DNA.
We believe this observation fits the expected in vivo dynamic range of DNA. The
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interaction among two biomolecules is not necessarily specific or potent because spe-
cificity relies on the biological context. These interactions are not only about specific
ligand-receptor bindings, but also about the non-specific ones. As binding depends
not only on the dissociation constant, but also on concentration, some interesting
effects can be seen. How non-specific interactions can affect specific interactions
between molecules of lower concentrations is often elusive. In this study, the vari-
ation of DNA concentration in blood would regulate TNF-α’s action.
It is known that the existing therapy regarding TNF-α is insufficient and it is largely
a consequence of the relative ignorance we have about how this player affects and
is affected by the various molecular events in which it is involved. To develop an
appropriate small molecule for this end, it is needed a detailed study of how TNF-
α and its receptors are regulated, including their concentration, conformation, and
oligomerisation states. Our work scratches the hypothesis of how the physical envir-
onment of this protein can be determinant for its structure and consequent activity.
Summarising, this dissertation’s main goal is to demonstrate DNA oligomers as active
units that can be used as bionanotools in studies at the molecular level. Also, DNA
as a coding unit is able to perform operations at levels that current computation
methods are not able to achieve, while being useful to model systems and retrieve
information from them. At last, but not the least, we generated high-entropy struc-
tures that could be similar to the ones formed in vivo in DNA-related pathologies.
The link between these DNA complex and unspecific structures to the activation
of proteins, such as TNF-α, by the modification of their physical environment is
another great issue that this dissertation tries to unveil.
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6
Outlook
6.1 DNA-Based Diversity Modelling and Analysis
To prove that the DDMA method can be used in a real DECL selection, we are
planning to explore the synergic binding of two vancomycins with a dAdA modified
resin. The goal is to demonstrate DDMA can distinguish populations with no (no
vancomycin), weak (one vancomycin), or strong binders (two vancomycins). In this
selection, each small molecule will be carrying an oligonucleotide strand with very di-
verse sequences, the coding regions. Therefore, the diverse oligonucleotide segments
attached to the small molecules should take part in the self-assembly dynamics phe-
nomenons we have observed.
Later, we want to further develop this method for modelling large and dynamic het-
erogeneous populations using DNA libraries. The goal is to develop a toolbox that
can be easily adapted to create any kind of simulation. As in an ’enclosed ecosystem’,
where different variables can be applied and results can be read quickly.
We would like also to understand the molecular mechanism behind the formation of
the high-entropy DNA structures and to know if these are associated with patho-
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physiological conditions. And if so, how.
6.2 Physical Environment Regulation of TNF-α Activity
For this project, I envision the unravelling of the monomers’ assembling dynamics
as the number one goal. The follow-up of this discovery is the possibility to develop
improved small molecules, or other entities, able to disrupt these protein-protein or
protein-DNA interactions.
Immediately, we are focusing on determining different DNA shapes affinity to TNF-
α in a more accurate way using MST. Also, we plan to image with AFM TNF-α
co-incubated with DNA. We expect to see the formation or not, with or without
DNA, respectively, of stabilised TNF-α oligomers.
The development of a switchable TNF-α construct is also in our plans. However, the
modifications we created so far decreased its activity and binding affinity to DNA.
More development must be done on this field, probably with the use of engineered
proteins. For now, we will setup a system where TNF-α can interact with DNA-
biotin in the presence or absence of SA beads. In cell culture, we expect to see a
clear ’on/off’ effect with the co-incubation or not with beads. It is not a protein
switch, but more of a DNA sequester experiment.
At last, we would like to understand in more detail how TNF-α’s interaction with the
physical environment, e.g., negatively charged polymers, translates into the molecular
biology level. We want to study the effect this interaction might have on the NF-κB
pathway.
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7
Summary
This dissertation focuses on rationalised DNA design as a tool for the discovery and
development of new biotechnological methods, as well as understanding the biological
function of DNA beyond the storage of genetic information. This study is comprised
of two main areas of study: (i) the use of DNA as a coding unit to illustrate the
relationship between code-diversity and dynamics of self-assembly; and (ii) the use
of DNA as an active unit that interacts and regulates a target protein.
DNA-Based Diversity Modelling and Analysis In the study of DNA as a coding unit
in code-diversity and dynamics of self-assembly, we developed the DDMA method.
Using PCR and RT-PCR, we studied the diversity and evolution of synthetic oli-
gonucleotide populations. The manipulation of critical conditions, with monitoring
and interpretation of their effects, helped understanding how PCR amplification can
reflect the diversity of a DNA sample.
Experimentally, this study was performed by monitoring the fluorescence signal de-
velopment during RT-PCR amplification. When amplifying one template, there was
generation of perfectly matched duplexes, which translated into a sigmoidal curve
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on the RT-PCR. However, when amplifying a diverse sample, such as an aptamer
library, this sigmoid became a bell-shaped curve, see Figure 7.1. We hypothesise this
phenomenon occurs because:
1. Initially, the amount of primers is higher than the template DNA. For early
cycles of amplification, each primer has the possibility to create a fully com-
plementary dsDNA by polymerase action. Then, the perfectly matched DNA
duplexes intercalate the fluorescent dye. The fluorescent signal increases expo-
nentially.
2. In later cycles, during the stationary phase there are two possibilities. If a
population only has one template, the population of dsDNA will reshuffle and
find a perfect match in a population of only forward and reverse strands of
the same template. The fluorescent dye is able to intercalate these structures
and the signal intensity remains unchanged. If a population is very diverse,
when primer concentrations are lower, every time there is a temperature cycle
and the dsDNA melt, there is reshuffling. As the subsequent annealing phase
occurs, the strands are less likely to meet their fully complementary partner.
The perfect match between complementary strands occurs in an exponentially
smaller extent, thereby causing a decrease in the fluorescence signal.
DDMA has great value for the study of: (a) code-diversity, convenient in a DNA-
based selection method, so semi-quantitation can evaluate a selection development
and the population’s behaviour can indicate the quality; (b) self-assembly dynamics,
for the simulation of a real evolution, emulating a society where selective pressures
direct the population’s adaptation; and (c) development of high-entropy DNA struc-
tures, in order to understand how similar unspecific DNA structures are formed in
certain pathologies, such as in auto-immune diseases.
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Figure 7.1: RT-PCR experiment using DNA libraries of different diversities. Xn
corresponds to the diverse libraries, where n indicates the number of randomised
nucleotides, from two to 20.
Physical Environment Regulation of TNF-α Activity To explore DNA as a regulatory
unit in TNF-α interaction and activity modulation, we investigated the DNA’s in-
fluence on its spatial conformation through physical interaction. Active TNF-α is
a trimer and the protein-protein interactions between its monomers are a prom-
ising target for drug development. It has been hypothesised that TNF-α forms a
very intricate network after its activation between monomers and receptors, but the
mechanism is still not completely clear.
During our research, we estimated the non-specific DNA binding to TNF-α in the
micro-molar range, see Figure 7.2. Cell toxicity assays confirmed this interaction,
where DNA consistently enhanced TNF-α’s cytotoxic effect. Further binding and
structural studies lead to the same conclusion that DNA binds and interferes with
TNF-α structure. The probable reason for this binding is the unspecific interaction
between the positively charged TNF-α and the negatively charged DNA.
The physical interaction between two biomolecules through, e.g., electrostatic inter-
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action is often neither potent nor specific. However, a specific regulatory mechanism
can occur when the fluctuation of the concentration of one component is in the range
of Kd value. From the TNF-α-DNA interaction study, a new mechanism to regulate
the biological activity of TNF-α has been suggested.
Figure 7.2: Band-shift assay resulting from the incubation of 50 µm TNF-α with
1 µm DNA: Cy5-ssDNA (1 and 2), Cy5-half-dsDNA (3 and 4) and Cy5-yDNA (5
and 6). Lanes 1, 3 and 5 correspond to the no protein control. Lane number 7
corresponds to TNF-α only control. 4% agarose gel.
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gleicher oder ähnlicher Form einer anderen Prüfungsbehörde vorgelegt.
Die vorliegende Dissertation wurde am B CUBE - Center for Molecular Bioengin-
eering der Technischen Universität Dresden in der Arbeitsgruppe Biomolecular In-
teractions von Prof. Dr. Yixin Zhang in der Zeit vom Mai 2013 bis Mai 2016 unter
wissenschaftlicher Betreuung von Prof. Dr. Carsten Werner angefertigt.
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[6] T. Dršata and F. Lankaš, “Multiscale modelling of DNA mechanics,” Journal
of Physics: Condensed Matter, vol. 27, p. 323102, 2015.
[7] N. C. Seeman, “DNA in a material world,” Nature, vol. 421, pp. 427–31, 2003.
[8] B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. Walter, Molecular
Biology of the Cell. New York: Garland Science, 4th ed., 2002.
[9] J. Bednar, R. A. Horowitz, S. A. Grigoryev, L. M. Carruthers, J. C. Hansen,
A. J. Koster, and C. L. Woodcock, “Nucleosomes, linker DNA, and linker
histone form a unique structural motif that directs the higher-order folding and
compaction of chromatin,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 95, pp. 14173–8, 1998.
142
[10] S. Peng, T. L. Derrien, J. Cui, C. Xu, and D. Luo, “From cells to DNA ma-
terials,” Materials Today, vol. 15, no. 5, pp. 190–4, 2012.
[11] A. Ellington and J. D. Pollard, “Synthesis and purification of oligonucleotides,”
in Current Protocols in Molecular Biology, vol. Chapter 2, p. Unit 2.11, 1998.
[12] A. Shivalingam and T. Brown, “Synthesis of chemically modified DNA,” Bio-
chemical Society Transactions, vol. 44, pp. 709–15, 2016.
[13] B. Hall, J. M. Micheletti, P. Satya, K. Ogle, J. Pollard, and A. D. Ellington,
“Design, synthesis, and amplification of DNA pools for in vitro selection,” in
Current Protocols in Molecular Biology, no. Unit 24.2, pp. 1–27, 2009.
[14] H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Mat-
sumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira, “A Toll-like receptor
recognizes bacterial DNA,” Nature, vol. 408, pp. 740–5, 2000.
[15] B. Goldberg, H. B. Urnovitz, and R. B. Stricker, “Beyond danger: Unmethyl-
ated CpG dinucleotides and the immunopathogenesis of disease,” Immunology
Letters, vol. 73, pp. 13–8, 2000.
[16] R. S. Illingworth and A. P. Bird, “CpG islands - ’A rough guide’,” FEBS
Letters, vol. 583, pp. 1713–20, 2009.
[17] J. Vollmer, R. Weeratna, P. Payette, M. Jurk, C. Schetter, M. Laucht,
T. Wader, S. Tluk, M. Liu, H. L. Davis, and A. M. Krieg, “Characterization
of three CpG oligodeoxynucleotide classes with distinct immunostimulatory
activities,” European Journal of Immunology, vol. 34, pp. 251–62, 2004.
[18] V. J. Schüller, S. Heidegger, N. Sandholzer, P. C. Nickels, N. A. Suhartha,
S. Endres, C. Bourquin, and T. Liedl, “Cellular immunostimulation by CpG-
sequence-coated DNA origami structures,” ACS Nano, vol. 5, no. 12, pp. 9696–
702, 2011.
[19] M. Nishikawa, M. Matono, S. Rattanakiat, N. Matsuoka, and Y. Takakura,
“Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape
formation,” Immunology, vol. 124, pp. 247–55, 2008.
[20] D. S. Lee, H. Qian, C. Y. Tay, and D. T. Leong, “Cellular processing and
destinies of artificial DNA nanostructures,” Chem Soc Rev, vol. 45, pp. 4199–
225, 2016.
143
[21] N. Matsuoka, M. Nishikawa, K. Mohri, S. Rattanakiat, and Y. Takakura,
“Structural and immunostimulatory properties of Y-shaped DNA consisting of
phosphodiester and phosphorothioate oligodeoxynucleotides,” Journal of Con-
trolled Release, vol. 148, pp. 311–6, 2010.
[22] C. Cheng, M. Omura-Minamisawa, Y. Kang, T. Hara, I. Koike, and T. Inoue,
“Quantification of circulating cell-free DNA in the plasma of cancer patients
during radiation therapy,” Cancer Science, vol. 100, no. 2, pp. 303–9, 2009.
[23] A. Szpechcinski, J. Chorostowska-Wynimko, R. Struniawski, W. Kupis,
P. Rudzinski, R. Langfort, E. Puscinska, P. Bielen, P. Sliwinski, and T. Or-
lowski, “Cell-free DNA levels in plasma of patients with non-small-cell lung
cancer and inflammatory lung disease,” British Journal of Cancer, vol. 113,
pp. 476–83, 2015.
[24] K. Haugbro, J. C. Nossent, T. Winkler, Y. Figenschau, and O. P. Rekvig,
“Anti-dsDNA antibodies and disease classification in antinuclear antibody pos-
itive patients: The role of analytical diversity,” Annals Rheumatic Diseases,
vol. 63, pp. 386–94, 2004.
[25] R. K. Saiki, S. Scharf, F. Faloona, K. B. Mullis, G. T. Horn, H. A. Erlich,
and N. Arnheim, “Enzymatic amplification of β-globin genomic sequences and
restriction site analysis for diagnosis of sickle cell anemia,” Science, vol. 230,
pp. 1350–4, 1985.
[26] R. K. Saiki, D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B.
Mullis, and H. A. Erlich, “Primer-directed enzymatic amplification of DNA
with a thermostable DNA polymerase,” Science (New York, N.Y.), vol. 239,
pp. 487–91, 1988.
[27] J. T. Keer, “Quantitative real-time PCR Analysis,” in Essentials of Nucleic
Acid Analysis: A Robust Approach, pp. 132–66, 2008.
[28] J. E. Hardingham, A. Chua, J. W. Wrin, A. Shivasami, I. Kanter, N. C.
Tebbutt, and T. J. Price, “Polymerase chain reaction: Types, utilities and lim-
itations,” in BRAF V600E Mutation Detection Using High Resolution Probe
Melting Analysis, Polymerase Chain Reaction (P. Hernandez-Rodriguez, ed.),
pp. 157–72, intech ed., 2012.
[29] X. Tang, S. L. Morris, J. J. Langone, and L. E. Bockstahler, “Simple and
effective method for generating single-stranded DNA targets and probes,” Bi-
oTechniques, vol. 40, pp. 759–62, 2006.
144
[30] C. Marimuthu, T.-H. Tang, J. Tominaga, S.-C. Tan, and S. C. B. Gopinath,
“Single-stranded DNA (ssDNA) production in DNA aptamer generation,”
Analyst, vol. 137, pp. 1307–15, 2012.
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F. Kranz, M. Rudin, S. Melkko, J. Scheuermann, and D. Neri, “A portable al-
bumin binder from a DNA-encoded chemical library,” Angewandte Chemie -
International Edition, vol. 47, pp. 3196–201, 2008.
[128] M. Leimbacher, Y. Zhang, L. Mannocci, M. Stravs, T. Geppert, J. Scheuer-
mann, G. Schneider, and D. Neri, “Discovery of small-molecule interleukin-2
inhibitors from a DNA-encoded chemical library,” Chemistry - A European
Journal, vol. 18, pp. 7729–37, 2012.
[129] R. K. Thalji, J. J. McAtee, S. Belyanskaya, M. Brandt, G. D. Brown, M. H.
Costell, Y. Ding, J. W. Dodson, S. H. Eisennagel, R. E. Fries, J. W. Gross,
M. R. Harpel, D. A. Holt, D. I. Israel, L. J. Jolivette, D. Krosky, H. Li, Q. Lu,
T. Mandichak, T. Roethke, C. G. Schnackenberg, B. Schwartz, L. M. Shew-
chuk, W. Xie, D. J. Behm, S. A. Douglas, A. L. Shaw, and J. P. Marino, “Dis-
covery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of sol-
uble epoxide hydrolase,” Bioorganic and Medicinal Chemistry Letters, vol. 23,
pp. 3584–8, 2013.
[130] A. G. Gilmartin, T. H. Faitg, M. Richter, A. Groy, M. a. Seefeld, M. G. Darcy,
X. Peng, K. Federowicz, J. Yang, S.-Y. Zhang, E. Minthorn, J.-P. Jaworski,
M. Schaber, S. Martens, D. E. McNulty, R. H. Sinnamon, H. Zhang, R. B.
Kirkpatrick, N. Nevins, G. Cui, B. Pietrak, E. Diaz, A. Jones, M. Brandt,
B. Schwartz, D. a. Heerding, and R. Kumar, “Allosteric Wip1 phosphatase in-
hibition through flap-subdomain interaction,” Nature chemical biology, vol. 10,
pp. 181–7, 2014.
[131] S. Barluenga, C. Zambaldo, H. A. Ioannidou, M. Ciobanu, P. Morieux, J. P.
Daguer, and N. Winssinger, “Novel PTP1B inhibitors identified by DNA dis-
play of fragment pairs,” Bioorganic and Medicinal Chemistry Letters, vol. 26,
pp. 1080–5, 2016.
[132] H. Yang, P. F. Medeiros, K. Raha, P. Elkins, K. E. Lind, R. Lehr, N. D. Adams,
J. L. Burgess, S. J. Schmidt, S. D. Knight, K. R. Auger, M. D. Schaber, G. J.
Franklin, Y. Ding, J. L. Delorey, P. A. Centrella, S. Mataruse, S. R. Skinner,
M. A. Clark, J. W. Cuozzo, and G. Evindar, “Discovery of a potent class of
PI3Kα inhibitors with unique binding mode via encoded library technology
(ELT),” ACS Medicinal Chemistry Letters, no. 5, pp. 531–6, 2015.
[133] P. A. Harris, B. W. King, D. Bandyopadhyay, S. B. Berger, N. Campobasso,
C. A. Capriotti, J. A. Cox, L. Dare, X. Dong, J. N. Finger, L. C. Grady, S. J.
Hoffman, J. U. Jeong, J. Kang, V. Kasparcova, A. S. Lakdawala, R. Lehr,
154
D. E. McNulty, R. Nagilla, M. T. Ouellette, C. S. Pao, A. R. Rendina, M. C.
Schaeffer, J. D. Summerfield, B. A. Swift, R. D. Totoritis, P. Ward, A. Zhang,
D. Zhang, R. W. Marquis, J. Bertin, and P. J. Gough, “DNA-encoded library
screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and mono-
selective receptor interacting protein 1 (RIP1) kinase inhibitors,” Journal of
Medicinal Chemistry, vol. 59, pp. 2163–78, 2016.
[134] A. R. Chandrasekaran, “Programmable DNA scaffolds for spatially-ordered
protein assembly,” Nanoscale, vol. 8, pp. 4436–46, 2016.
[135] J. H. Chen and N. C. Seeman, “Synthesis from DNA of a molecule with the
connectivity of a cube,” Nature, vol. 350, pp. 631–3, 1991.
[136] E. Winfree, F. Liu, L. A. Wenzler, and N. C. Seeman, “Design and self-assembly
of two-dimensional DNA crystals,” Nature, vol. 394, pp. 539–44, 1998.
[137] C. Mao, W. Sun, and N. C. Seeman, “Designed two-dimensional DNA hol-
liday junction arrays visualized by atomic force microscopy,” Journal of the
American Chemical Society, vol. 121, pp. 5437–43, 1999.
[138] H. Yan, X. Zhang, Z. Shen, and N. C. Seeman, “A robust DNA mechanical
device controlled by hybridization topology,” Nature, vol. 415, pp. 62–5, 2002.
[139] J. Zheng, J. J. Birktoft, Y. Chen, T. Wang, R. Sha, P. E. Constantinou, S. L.
Ginell, C. Mao, and N. C. Seeman, “From molecular to macroscopic via the
rational design of a self-assembled 3D DNA crystal,” Nature, vol. 461, pp. 74–7,
2009.
[140] S. Sellner, S. Kocabey, K. Nekolla, F. Krombach, T. Liedl, and M. Re-
hberg, “DNA nanotubes as intracellular delivery vehicles in vivo,” Biomateri-
als, vol. 53, pp. 453–63, 2015.
[141] M. R. Jones, N. C. Seeman, and C. a. Mirkin, “Programmable materials and
the nature of the DNA bond,” Science, vol. 347, no. 6224, pp. 1–11, 2015.
[142] S. M. Douglas, I. Bachelet, and G. M. Church, “A logic-gated nanorobot for
targeted transport of molecular payloads,” Science, vol. 335, pp. 831–4, 2012.
[143] S. M. Douglas, H. Dietz, T. Liedl, B. Hogberg, F. Graf, and W. M. Shih, “Self-
assembly of DNA into nanoscale three-dimensional shapes,” Nature, vol. 21,
pp. 414–8, 2009.
155
[144] M. Cieplak and W. Kutner, “Artificial biosensors: How can molecular imprint-
ing mimic biorecognition?,” Trends in Biotechnology, pp. 1–20, 2016.
[145] J. B. Lee, S. Peng, D. Yang, Y. H. Roh, H. Funabashi, N. Park, E. J. Rice,
L. Chen, R. Long, M. Wu, and D. Luo, “A mechanical metamaterial made
from a DNA hydrogel,” Nature Nanotechnology, vol. 7, pp. 816–20, 2012.
[146] Y. Li, Y. D. Tseng, S. Y. Kwon, L. D’Espaux, J. S. Bunch, P. L. McEuen,
and D. Luo, “Controlled assembly of dendrimer-like DNA,” Nature Materials,
vol. 3, pp. 38–42, 2004.
[147] S. Chatterjee, J. B. Lee, N. V. Valappil, D. Luo, and V. M. Menon, “Probing Y-
shaped DNA structure with time-resolved FRET,” Nanoscale, vol. 4, pp. 1568–
71, 2012.
[148] S. H. Um, J. B. Lee, N. Park, S. Y. Kwon, C. C. Umbach, and D. Luo, “Enzyme-
catalysed assembly of DNA hydrogel,” Nature Materials, vol. 5, pp. 797–801,
2006.
[149] C. Buranachai, S. A. McKinney, and T. Ha, “Single molecule nanometronome,”
Nano Letters, vol. 6, no. 3, pp. 496–500, 2006.
[150] A. Kuzuya, R. Watanabe, Y. Yamanaka, T. Tamaki, M. Kaino, and Y. Ohya,
“Nanomechanical DNA origami pH sensors,” Sensors, vol. 14, pp. 19329–35,
2014.
[151] S. Roweis, E. Winfree, R. Burgoyne, N. V. Chelyapov, M. F. Goodman,
P. W. K. Rothemund, and L. M. Adleman, “A sticker based model for DNA
computation,” Journal of Computational Biology, vol. 5, no. 4, pp. 615–29,
1998.
[152] L. M. Adleman, “Molecular computation of solutions to combinatorial prob-
lems,” Science, vol. 266, no. 5187, pp. 1021–4, 1994.
[153] L. Qian and E. Winfree, “Scaling up digital circuit computation with DNA
strand displacement cascades,” Science, vol. 332, pp. 1196–201, 2011.
[154] L. Qian, E. Winfree, and J. Bruck, “Neural network computation with DNA
strand displacement cascades,” Nature, vol. 475, pp. 368–72, 2011.
[155] J. Markman, “DNA is the new data,” Forbes, 2016.
156
[156] D. Meyer, “Why Microsoft just bought 10 million strands of DNA,” Fortune,
2016.
[157] D. Gil, A. Ferrández, H. Mora-Mora, and J. Peral, “Internet of things: A
review of surveys based on context aware intelligent services,” Sensors, vol. 16,
p. 1069, 2016.
[158] G. M. Church, Y. Gao, and S. Kosuri, “Next-generation digital information
storage in DNA,” Science, vol. 337, p. 1628, 2012.
[159] T. Palmer, “Build imprecise supercomputers,” Nature, vol. 526, pp. 2–3, 2015.
[160] T. N. Palmer and M. O’Shea, “Solving difficult problems creatively: A role
for energy optimised deterministic/stochastic hybrid computing,” Frontiers in
Computational Neuroscience, vol. 9, pp. 1–5, 2015.
[161] A. Extance, “How DNA could store all the world’s data,” Nature, vol. 537,
pp. 22–4, 2016.
[162] M. Austin, “Species distribution models and ecological theory: A critical as-
sessment and some possible new approaches,” Ecological Modelling, vol. 200,
pp. 1–19, 2007.
[163] D. N. Reznick and C. K. Ghalambor, “The population ecology of contemporary
adaptations: What empirical studies reveal about the conditions that promote
adaptive evolution,” Genetica, vol. 112-113, pp. 183–98, 2001.
[164] H. T. Idriss and J. H. Naismith, “TNF-α and the TNF receptor superfam-
ily: Structure-function relationship(s),” Microscopy Research and Technique,
vol. 50, pp. 184–95, 2000.
[165] N. Vanlangenakker, M. J. M. Bertrand, P. Bogaert, P. Vandenabeele, and T. V.
Berghe, “TNF-induced necroptosis in L929 cells is tightly regulated by multiple
TNFR1 complex I and II members,” Cell Death and Disease, vol. 2, p. e230,
2011.
[166] S. Fulda, “Therapeutic exploitation of necroptosis for cancer therapy,” Sem-
inars in Cell and Developmental Biology, vol. 35, pp. 51–6, 2014.
[167] J. R. Bradley, “The role of nuclear organization in cancer,” Journal of Patho-
logy, vol. 214, pp. 149–60, 2008.
157
[168] B. B. Aggarwal, S. C. Gupta, and J. H. Kim, “Historical perspectives on tumor
necrosis factor and its superfamily: 25 years later, a golden journey,” Blood,
vol. 119, no. 3, pp. 651–665, 2012.
[169] D. Intiso, M. M. Zarrelli, G. Lagioia, F. D. Rienzo, C. Checchia De Ambrosio,
P. Simone, P. Tonali, and R. P. Cioffi, “Tumor necrosis factor alpha serum levels
and inflammatory response in acute ischemic stroke,” Neurological Sciences,
vol. 24, pp. 390–6, 2003.
[170] V. Michalaki, K. Syrigos, P. Charles, and J. Waxman, “Serum levels of IL-6
and TNF-α correlate with clinicopathological features and patient survival in
patients with prostate cancer,” British Journal of Cancer, vol. 90, pp. 2312–6,
2004.
[171] O. Arican, M. Aral, S. Sasmaz, and P. Ciragil, “Serum levels of TNF-α, IFN-
γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and
correlation with disease severity,” Mediators of Inflammation, vol. 2005, no. 5,
pp. 273–9, 2005.
[172] T. Horiuchi, H. Mitoma, S. I. Harashima, H. Tsukamoto, and T. Shimoda,
“Transmembrane TNF-α: Structure, function and interaction with anti-TNF
agents,” Rheumatology, vol. 49, pp. 1215–28, 2010.
[173] D. Aderka, H. Engelmann, Y. Maor, C. Brakebusch, and D. Wallach, “Stabil-
ization of the bioactivity of tumor necrosis factor by its soluble receptors,” The
Journal of Eperimental Medicine, vol. 175, pp. 323–9, 1992.
[174] S. Nagata, R. Hanayama, and K. Kawane, “Autoimmunity and the clearance
of dead cells,” Cell, vol. 140, pp. 619–30, 2010.
[175] G. Hartmann, A. Krug, A. Eigler, J. Moeller, J. Murphy, R. Albrecht, and
S. Endres, “Specific suppression of human tumor necrosis factor-α synthesis
by antisense oligodeoxynucleotides,” Antisense and Nucleic Acid Drug Devel-
opment, vol. 6, pp. 291–9, 1996.
[176] G. Hartmann, A. Krug, K. Waller-Fontaine, and S. Endres, “Oligodeoxy-
nucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis
factor: Dependence on phosphorothioate modification and reversal by hep-
arin,” Molecular Medicine, vol. 2, no. 4, pp. 429–38, 1996.
[177] H. Pfister, T. Hennet, and T. W. Jungi, “Lipopolysaccharide synergizes with
tumour necrosis factor-α in cytotoxicity assays,” Immunology, vol. 77, pp. 473–
6, 1992.
158
[178] E. P. Sampaio, E. N. Sarno, R. Galilly, Z. A. Cohn, and G. Kaplan, “Thalidom-
ide selectively inhibits tumor necrosis factor α production by stimulated human
monocytes,” The Journal of Experimental Medicine, vol. 173, pp. 699–703,
1991.
[179] J. F. Cheng, A. Ishikawa, Y. Ono, T. Arrhenius, and A. Nadzan, “Novel chro-
mene derivatives as TNF-α inhibitors,” Bioorganic and Medicinal Chemistry
Letters, vol. 13, pp. 3647–50, 2003.
[180] Y. Mukai, T. Nakamura, M. Yoshikawa, Y. Yoshioka, S.-i. Tsunoda, S. Na-
kagawa, Y. Yamagata, and Y. Tsutsumi, “Solution of the structure of the
TNF-TNFR2 complex,” Science Signaling, vol. 3, no. 148, p. ra83, 2010.
[181] F. Bazzoni and B. Beutler, “The tumor necrosis factor ligand and receptor
families,” Seminars in Medicine of the Beth Israel Hospital, Boston, vol. 334,
no. 26, pp. 1717–25, 1996.
[182] M. J. Eck and S. R. Sprang, “The structure of tumor necrosis factor-α at 2.6 Å
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